<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_XCRM100128 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEgr4 jpg ?>
<?FILEgr5 jpg ?>
<?FILEgr6 jpg ?>
<?FILEfx1 jpg ?>
<?FILEmmc1 pdf ?>
<?FILEmmc2 xlsx ?>
<?FILEmmc3 xlsx ?>
<?FILEmmc4 xlsx ?>
<?FILEmmc5 xlsx ?>
<?FILEmmc6 xlsx ?>
<?FILEmmc7 xlsx ?>
<?FILEmmc8 xlsx ?>
<?FILEmmc9 pdf ?>
<?properties open_access?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Cell Rep Med</journal-id>
    <journal-id journal-id-type="iso-abbrev">Cell Rep Med</journal-id>
    <journal-title-group>
      <journal-title>Cell Reports Medicine</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2666-3791</issn>
    <publisher>
      <publisher-name>Elsevier</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7659504</article-id>
    <article-id pub-id-type="pii">S2666-3791(20)30170-1</article-id>
    <article-id pub-id-type="doi">10.1016/j.xcrm.2020.100128</article-id>
    <article-id pub-id-type="publisher-id">100128</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au1">
        <name>
          <surname>Essegian</surname>
          <given-names>Derek</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">4</xref>
      </contrib>
      <contrib contrib-type="author" id="au2">
        <name>
          <surname>Khurana</surname>
          <given-names>Rimpi</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">4</xref>
      </contrib>
      <contrib contrib-type="author" id="au3">
        <name>
          <surname>Stathias</surname>
          <given-names>Vasileios</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
      </contrib>
      <contrib contrib-type="author" id="au4">
        <name>
          <surname>Schürer</surname>
          <given-names>Stephan C.</given-names>
        </name>
        <email>sschurer@med.miami.edu</email>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
        <xref rid="fn2" ref-type="fn">5</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <aff id="aff1"><label>1</label>Department of Pharmacology, Miller School of Medicine, University of Miami, Miami, USA</aff>
      <aff id="aff2"><label>2</label>Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA</aff>
      <aff id="aff3"><label>3</label>Institute for Data Science &amp; Computing, University of Miami, Miami, USA</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>∗</label>Corresponding author <email>sschurer@med.miami.edu</email></corresp>
      <fn id="fn1">
        <label>4</label>
        <p id="ntpara0015">These authors contributed equally</p>
      </fn>
      <fn id="fn2">
        <label>5</label>
        <p id="ntpara0020">Lead Contact</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>20</day>
      <month>10</month>
      <year>2020</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <day>20</day>
      <month>10</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>20</day>
      <month>10</month>
      <year>2020</year>
    </pub-date>
    <volume>1</volume>
    <issue>7</issue>
    <elocation-id>100128</elocation-id>
    <history>
      <date date-type="received">
        <day>29</day>
        <month>10</month>
        <year>2019</year>
      </date>
      <date date-type="rev-recd">
        <day>25</day>
        <month>4</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>24</day>
        <month>9</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2020 The Authors</copyright-statement>
      <copyright-year>2020</copyright-year>
      <license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="abs0010">
      <title>Summary</title>
      <p>The approval of the first kinase inhibitor, Gleevec, ushered in a paradigm shift for oncological treatment—the use of genomic data for targeted, efficacious therapies. Since then, over 48 additional small-molecule kinase inhibitors have been approved, solidifying the case for kinases as a highly druggable and attractive target class. Despite the role deregulated kinase activity plays in cancer, only 8% of the kinome has been effectively “drugged.” Moreover, 24% of the 634 human kinases are understudied. We have developed a comprehensive scoring system that utilizes differential gene expression, pathological parameters, overall survival, and mutational hotspot analysis to rank and prioritize clinically relevant kinases across 17 solid tumor cancers from The Cancer Genome Atlas. We have developed the clinical kinase index (CKI) app (<ext-link ext-link-type="uri" xlink:href="http://cki.ccs.miami.edu" id="interref0010">http://cki.ccs.miami.edu</ext-link>) to facilitate interactive analysis of all kinases in each cancer. Collectively, we report that understudied kinases have potential clinical value as biomarkers or drug targets that warrant further study.</p>
    </abstract>
    <abstract abstract-type="graphical" id="abs0015">
      <title>Graphical Abstract</title>
      <fig id="undfig1" position="anchor">
        <graphic xlink:href="fx1"/>
      </fig>
    </abstract>
    <abstract abstract-type="author-highlights" id="abs0020">
      <title>Highlights</title>
      <p>
        <list list-type="simple" id="ulist0010">
          <list-item id="u0010">
            <p id="p0010">CKI is a novel method to prioritize dark kinases as cancer drug targets</p>
          </list-item>
          <list-item id="u0015">
            <p id="p0015">Expression of understudied kinases in tumors is prognostic of poor outcomes</p>
          </list-item>
          <list-item id="u0020">
            <p id="p0020">Dark kinases are likely clinically relevant cancer targets</p>
          </list-item>
          <list-item id="u0025">
            <p id="p0025">Cancer cell dependency correlates with tumor pathology and survival</p>
          </list-item>
        </list>
      </p>
    </abstract>
    <abstract abstract-type="teaser" id="abs0025">
      <p>Essegian et. al conduct a kinome-wide pan-cancer analysis and provide an intuitive interface to prioritize understudied kinases as prospective novel cancer drug targets. While many of the approved kinase drug targets rank high in each cancer cohort, several understudied kinases also appear to be clinically relevant and warrant further exploration.</p>
    </abstract>
    <kwd-group id="kwrds0010">
      <title>Keywords</title>
      <kwd>target validation</kwd>
      <kwd>clinical scoring system</kwd>
      <kwd>data integration</kwd>
      <kwd>human kinome</kwd>
      <kwd>cancer drug target</kwd>
      <kwd>understudied kinase</kwd>
      <kwd>druggable genome</kwd>
      <kwd>differential gene expression</kwd>
      <kwd>TNM score</kwd>
      <kwd>Kaplan-Meier survival analysis</kwd>
    </kwd-group>
  </article-meta>
  <notes>
    <p id="misc0010">Published: October 20, 2020</p>
  </notes>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p id="p0030">The human genome encodes about 634 kinases (pseudokinases included). However, as of 2019, only 49 kinases (8%) are currently primary targets of FDA-approved small-molecule cancer drugs<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> (<xref rid="fig1" ref-type="fig">Figure 1</xref>). Furthermore, 70% of these approved cancer kinase drug targets belong to the tyrosine kinase (TK) group. For several cancers, though, targeting the TK group has not been an effective strategy, despite overwhelming evidence of receptor TK dysregulation in those tumors.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> For example, TK inhibitors (TKIs) have shown little to no clinical efficacy in the treatment of bladder, esophageal, prostate, brain, and stomach cancers.<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref> While it has been firmly established that aberrant kinase activity indeed leads to cancer progression and metastasis in many cancers, researchers have not fully elucidated the ideal cancer-specific kinase targets or novel drug combinations to improve the standard of care.<fig id="fig1"><label>Figure 1</label><caption><p>Overview of Kinase TDLs</p><p>(A) There are 634 kinases annotated on Pharos. In total, 8.2% are considered Tclin, and 151 of 634 are considered “understudied”; these represent kinases that bear Tdark, Tbio, and Tchem annotations.</p><p>(B) Certain groups of kinases are historically understudied. The CMGC group, CAMK group, and “other” group kinases are enriched for understudied kinases, while TKs have been extensively explored.</p></caption><graphic xlink:href="gr1"/></fig></p>
    <p id="p0035">To promote the study and validation of novel kinase targets, we herein describe a kinase-prioritization index using data from The Cancer Genome Atlas (TCGA) across 17 cancer types for researchers to use as a starting point for further investigation (<xref rid="mmc2" ref-type="supplementary-material">Table S1</xref> provides an overview of the available cancer data). By combining differential gene expression (DGE), Kaplan-Meier (KM) survival, and mutational hotspot and clinical/pathological correlation analyses, we have developed a scoring system, the clinical kinase index (CKI), to prioritize <italic>clinically</italic> relevant kinase targets for each cancer cohort (<xref rid="fig2" ref-type="fig">Figure 2</xref>). We define “clinically relevant” as having a correlation or relationship to critical clinical benchmarks, such as tumor grade and American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> In short, we have analyzed and highlighted kinases whose mRNA expression levels appear to be prognostic and associated with the progression of cancer. Since kinase activity does not always correspond with mRNA expression levels (e.g., mTOR oncogenic activity is due to an increase in activation via phosphorylation<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref>), we also leveraged TCGA genomic data and prioritized kinases that confer a selective advantage to tumor development as measured by the accrual and clustering of mutations at specific regions of their amino acid sequence. Moreover, by integrating our data with external target annotation resources, we evaluated the CKI scores based on a number of clinical classifications, such as target development level (TDL),<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> which classifies a target based on available target validation knowledge (Tclin, Tchem, Tbio, and Tdark); kinase family class (which corresponds to phylogenecity and substrates); clinical trial data; and MOA (mechanism of action) of approved drugs for each cancer type.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref><fig id="fig2"><label>Figure 2</label><caption><p>Outline of the CKI Workflow</p><p>(A) Data were extracted from multiple sources for curation, filtering, and normalization.</p><p>(B) mRNA levels and mutational hotspots were analyzed to generate DGE analyses and mutational frequencies. mRNA levels were also correlated with survival and clinical/pathological outcomes. Various statistical methods were employed, and all significant correlations were scored.</p><p>(C) Final CKI scores were generated and mapped to other data annotations for further analysis and interpretation.</p></caption><graphic xlink:href="gr2"/></fig></p>
    <p id="p0040">With over 175 kinase drugs currently in clinical trials, new targets are being evaluated, including AKT, aurora kinases, CHEK1, and CDK1.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Despite the large number of drugs that are being investigated, the majority of trials are for well-known, previously approved kinase targets such as EGFR, VEGFR, phosphatidylinositol 3-kinase <bold>(</bold>PI3K), and mTOR.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Nevertheless, there are still no small-molecule drugs that target kinases in the calmodulin-dependent protein kinase (CaMK), CK1, or AGC groups of kinases as their primary target (Ki &lt; 10 nM), notwithstanding increased evidence for their clinical relevance in cancer.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> The extent of such a misrepresentation has been highlighted by the NIH-funded Illuminating the Druggable Genome (IDG; <ext-link ext-link-type="uri" xlink:href="https://druggablegenome.net/" id="intref0015">https://druggablegenome.net/</ext-link>) project, where analysis concludes that 23.8% (151) of the 634 kinases are “understudied,” as they lack sufficient GeneRIFs, antibodies, citations in the literature, and potent chemical probes.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Consistent with this is the fact that the current kinase inhibitors target not only a narrow range of targets, but also a narrow range of pathways including angiogenesis, cell adhesion, immune system signaling (cytokine, T cell receptor, B cell receptor), and anti-apoptotic pathways.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> For example, all kinase inhibitors for renal cell carcinoma target angiogenic pathways.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> It is likely that the most optimal strategy for treating cancers is targeting multiple orthogonal pathways that work in a synergistic manner, as opposed to targeting kinases with overlapping pathways.<xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref> It has already been shown that this strategy may prevent or reduce the incidence of resistance pathways and kinome reprogramming, which is inevitable upon singular treatment with a highly specific kinase drug such as the EGFR inhibitor, lapatinib.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> The CKI is a tool that may be used to facilitate the exploration of clinically relevant new kinase drug targets for this purpose.</p>
    <p id="p0045">Along with this report, we have made available the CKI app (<ext-link ext-link-type="uri" xlink:href="http://cki.ccs.miami.edu/" id="intref0020">http://cki.ccs.miami.edu/</ext-link>) to access, interactively explore, download, and analyze all data and results of this study. With this study, we provide a resource for the scientific community where the clinical relevance of kinase genes across solid-tumor cancers can quickly be evaluated, especially for understudied kinases and cancers for which no approved first-line kinase therapy exists.</p>
  </sec>
  <sec id="sec2">
    <title>Results</title>
    <sec id="sec2.1">
      <title>The CKI Predicts Clinically Validated Kinase Targets</title>
      <p id="p0050">The CKI (<ext-link ext-link-type="uri" xlink:href="http://cki.ccs.miami.edu/" id="intref0025">http://cki.ccs.miami.edu/</ext-link>) serves the purpose of ranking and categorizing the clinical relevance of the entire kinome, with a special focus on understudied and dark kinases (<xref rid="fig3" ref-type="fig">Figure 3</xref>). To generate a CKI score for each kinase in each cancer cohort, four parameters were taken into consideration: DGE, KM survival, mutational hotspots, and clinical-pathological features. For each DGE, KM survival, and mutational hotspot, kinases received a score of 1 if there was statistical significance (see <xref rid="sec4.3" ref-type="sec">Method Details</xref>). Clinical and pathological data varied by cancer cohort; thus, a clinical score was generated using ANOVA analysis to determine if kinase expression correlated with progression through stage or grade. For each clinical-pathological parameter, there was a maximum score of 1. The raw CKI score for each kinase in a cancer cohort is the sum of the scores from DGE, survival, mutational analysis, and clinical scores. Raw scores were then divided by the total possible score and converted to percentages. For comparison across cancer cohorts, a rank-ordered list was also generated, which is available for analysis on the CKI app.<fig id="fig3"><label>Figure 3</label><caption><p>CKI scores by TDL and TCGA Cancer Cohort</p><p>Most cancers have average Tclin or Tchem scores that are significantly higher than the other TDLs. COAD, BRCA, LUSC, and PRAD have Tdark kinases that score, on average, higher than Tclin kinases. Furthermore, cancer-specific MOA targets tend to score the highest in the CKI. See also <xref rid="mmc3" ref-type="supplementary-material">Table S2</xref>.</p></caption><graphic xlink:href="gr3"/></fig></p>
      <p id="p0055">We have observed several trends in the CKI that may underscore the validity of our model and prioritization system. First, the CKI accurately prioritizes currently in-trial or approved drug targets for several cancers in the TCGA. As such, the average and median CKI scores for kinases that have been under clinical investigation are statistically significantly higher than those that have not in BRCA, head and neck squamous carcinoma (HNSC), renal clear cell (KIRC), lung adenocarcinoma (LUAD), lung squamous carcinoma (LUSC), rectal adenocarcinoma (READ), stomach adenocarcinoma (STAD), and thyroid carcinoma (THCA) cancers (p &lt; 0.05; <xref rid="mmc3" ref-type="supplementary-material">Table S2</xref>; <xref rid="mmc1" ref-type="supplementary-material">Data S1</xref>A–S1P). Furthermore, kinases that are MOA targets for approved drugs have significantly higher average and median CKI scores than non-MOA targets across all cancers (p &lt; 0.0001) (p &lt; 0.05 for select cancer cohorts; <xref rid="mmc2" ref-type="supplementary-material">Data S2</xref>A–S2N; <xref rid="mmc3" ref-type="supplementary-material">Table S2</xref>). These results generally suggest that less-studied kinases that rank as high as clinical kinases should be prioritized for further validation and clinical investigation. The majority of the high-scoring targets have been or are currently under investigation. For example, breast tumor kinase (<italic>PTK6</italic>) is the highest-ranking kinase for BRCA. This kinase is regarded as the key regulator in the oncogenic transformation of breast cancer, is overexpressed in &gt;80% of breast tumors, and is a highly attractive drug target<xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref> but has yet to enter clinical study. Other high-ranking kinases include those that are already in clinical trial or are FDA-approved targets, including PI3K kinases, MAP kinases, cyclin-dependent kinases, and aurora kinases. In the LUAD cohort, <italic>EGFR</italic> and <italic>MEK1</italic> rank highly; they represent targets of an approved lung cancer drug and compounds under investigation in several clinical trials.<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref> Similarly, <italic>MET</italic> and <italic>RET</italic> are among the high-scoring Tclin kinases for thyroid cancer. On average, we find that Tclin kinases had higher CKI scores, suggesting that many of the most clinically relevant or prognostic cancer kinases have already been studied extensively or are targets of approved drugs. The highest-scoring kinase in all datasets is <italic>PLK1</italic> (Tchem), with a CKI of 70.83 in kidney renal papillary cancer (KIRP). <italic>PLK1</italic>, like other Tchem kinases, ranks very highly and is an attractive target that has been under clinical investigation.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref>
<italic>PLK1</italic> is overexpressed in a number of cancers, and its activity has been linked to tumor growth, metastasis, and drug resistance.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref>
<italic>AURKA</italic> and <italic>AURKB</italic> also consistently scored high across every cancer cohort, as did other cell-cycle- and mitoses-related kinases (<italic>BUB1B</italic>, <italic>BUB1</italic>, <italic>CDK1</italic>).</p>
      <p id="p0060">In addition to Tclin kinases, multiple understudied kinases exhibit a high CKI score, thus indicating they are likely clinically relevant targets. Understudied kinases rank among the top 20 kinase genes for every cancer cohort scored. Several of these kinases appear to have mRNA levels that are prognostic of survival and tumor progression in multiple cancers. For example, <italic>ERN2</italic> (Tbio) is the second-highest-scoring kinase in BRCA and cholangiocarcinoma (CHOL) and sixth in LIHC. Because of its understudied nature, there are little to no cancer-related publications available to assess the literature evidence of <italic>ERN2</italic> as a potential target. <italic>ERN2</italic> does code for the protein IRE1β, which is part of the unfolded-protein stress response pathway.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> The unfolded protein response (UPR) pathway is a pro-survival pathway that is hijacked by cancer cells and thus has been a topic of discussion in the context of drug development.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> Other understudied kinases that score favorably in the majority of cancer cohorts include <italic>PKMYT1</italic> (Tchem), <italic>DCLK3</italic> (Tchem), <italic>BRSK1</italic> (Tchem), <italic>ADCK5</italic> (Tdark), and <italic>LMTK3</italic> (Tbio).</p>
      <p id="p0065">To compare the CKI scores across each cancer cohort, we performed a Spearman correlation rank analysis (see <xref rid="sec4.3" ref-type="sec">Method Details</xref>). Correlation between similar cancer cohorts based on tissue was the strongest, with LUSC and LUAD having significant overlap in top-ranking kinases, as was the same in KIRC with KIRP and colon adenocarcinoma (COAD) with READ (<xref rid="fig4" ref-type="fig">Figure 4</xref>). The top 25% of differentially overexpressed kinases in each cancer were also used as input for MSigDB<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> (gene set enrichment analysis) to compare kinase gene set enrichment overlap between each cancer. Spearman correlation using rank-ordered gene sets shows varying degrees of overlap among all cancer cohorts, but the strongest overlap was between LIHC and CHOL (85 gene sets in common). These data suggest that while many of the same key players are involved in the progression of multiple cancers, unique kinases emerge in each cohort. All cohorts were highly enriched for genes in the “FIRESTEIN_PROLIFERATION” and “MODULE_244” gene sets, which are genes required for the proliferation of colon cancer cells and genes responsible for DNA damage repair, respectively.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref><fig id="fig4"><label>Figure 4</label><caption><p>Overlap Analysis between Cancer Cohorts</p><p>(A) Gene set enrichment analysis was performed on the top-25%-scoring kinases for each cancer cohort using MSigDB. Pairwise overlap of 100 gene sets was calculated. Cohorts that share the highest degree of gene set enrichments include LIHC and CHOL, KIRC and CHOL, and THCA and CHOL.</p><p>(B) Spearman-rank correlation between CKIs of each cancer cohort. The greatest degree of correlation was present between cancers of the same tissue, including COAD and READ or LUAD and LUSC. THCA and BRCA had a slight negative correlation, suggestive of opposing clinical relevance of the same kinases in the different cancer cohorts.</p></caption><graphic xlink:href="gr4"/></fig></p>
    </sec>
    <sec id="sec2.2">
      <title>CKI Scores Are Supported by Achilles DepMap Data</title>
      <p id="p0070">Project Achilles and the Dependency Map (DepMap)<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> are efforts to identify genes essential for cancer cell proliferation and survival. Combining RNAi and CRISPR systematic loss-of-function screens in over 700 cancer cell lines for over 17,000 genes, researchers were able to obtain gene-level “dependency” scores while accounting for off-target shRNA/Cas-9 effects and other molecular features using the DEMETER2 computational method.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> We sought to benchmark the predictivity of our clinical kinase score against this experimentally derived data to explore the hypothesis that cancer kinase dependency in cell models correlates with clinical and pathological features associated with the dysregulation and overexpression of these kinases. Although we would not expect cell line data to perfectly correlate with clinical data, there should be some indication of clinical relevance extrapolated from cellular dependency. We used three independent datasets obtained from the DepMap portal to carry out these analyses: combined RNAi (Broad, Novartis, and Marcotte), shRNA Achilles (Avana), and CRISPR (Sanger). Each set had a different number of cell lines and disease models represented and a differing number of kinases annotated. For example, 565 of the 634 kinase genes in our dataset were present in the Achilles database. Of the 69 kinases that were not present in Achilles, 21 (30%) were understudied, which further underscores the inherent bias against these genes. Kinase genes were extracted from the datasets and were annotated as “dependent” if the dependency score was &lt; −1 (a cutoff defined by all DepMap studies<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref>) and “not dependent” if the dependency score was &gt; −1. Kruskall-Wallis tests (one-way ANOVA) were performed to determine if there was a significant difference in the distribution of mean CKI score in each cohort (dependent versus non-dependent) in the combined RNAi, Achilles, and Sanger datasets per disease type. Cell lines were grouped by tissue type: for example, all cell lines annotated “lung” were used to analyze CKI scores in both the LUSC and LUAD TCGA cohorts. Similarly, all cell lines annotated “kidney” were analyzed with kidney chromophobe carcinoma (KICH), KIRC, and KIRP cohorts. The results support the hypothesis that gene dependency relates to clinical relevance. “Dependent” kinases score significantly higher on the CKI than “not dependent” kinases for many cell lines, across all cancers and datasets (p value &lt; 0.05) (<xref rid="fig5" ref-type="fig">Figure 5</xref>; <xref rid="mmc4" ref-type="supplementary-material">Table S3</xref>). Of note, some Tclin kinases in our model scored low on the CKI but had significant dependency scores. Further investigation revealed that cyclin-dependent kinases (CDKs) tend to score “low,” as mRNA levels typically do not correspond with activity in tumors. CDKs, as their name suggest, have activity that is dependent on the abundance of cyclins. Also, as noted above, kinases such as mTOR have activity that is related to their post-translational modification. Despite these outliers, we can make the case that our kinase target ranking based on clinical phenotypes has a strong relationship with cancer-cell dependency in validated cancer cellular models.<fig id="fig5"><label>Figure 5</label><caption><p>Comparison of DepMap Scores and CKI</p><p>(A) Kinases from the ACH-000851 cell line (lung cancer) were divided into “dependent” (DepMap Score &lt; −1.0) and “not-dependent” groups. LUSC CKI scores were compared between the groups using the Kruskall-Wallis test. Kinases that are dependent in lung cancer cell lines also score significantly higher in the CKI (p = 2.13E−7). Black bars represent the 95% confidence interval of the mean. Distribution of scores is depicted as horizontal bar graphs superimposed on the boxplot.</p><p>(B) As DepMap scores (binned) increase (becoming less dependent), CKI scores decrease.</p><p>(C) ROC curve data using average CKI score and average dependency score with a cutoff of &lt; −1.0 shows that DepMap data may be a predictive model of clinical relevance (ROC = 0.776).</p></caption><graphic xlink:href="gr5"/></fig></p>
      <p id="p0075">Additionally, we employed both a Spearman rank correlation and a linear regression analysis to determine the strength of the relationship between the two variables, CKI score and dependency score, for each cell line in the DepMap datasets. When considering TMOA kinases (cancer-specific kinases that are annotated as MOA targets for an approved drug), there exists a moderate to strong relationship (p &lt; 0.05, R &lt; −0.6) between CKI and dependency (<xref rid="mmc4" ref-type="supplementary-material">Table S3</xref>). This suggests that targets with a low CKI score are likely to be not dependent in a particular cell line. Conversely, targets with a high CKI score are likely to be dependent. For example, in the UACC-893 breast cancer cell line, MOA target ERBB4 has a dependency score of only −0.18 and a corresponding CKI score of 3.65. However, MOA target PI3KCA has a dependency score of −1.8 and a CKI score of 14.38.</p>
      <p id="p0080">Finally, to evaluate the CKI as a predictive model for cellular dependency, receiver operating curves (ROC) were generated for cell lines from the DepMap datasets that showed significant differences in CKI scores between dependent and not-dependent kinases. A rank-ordered list of kinases (by CKI score) was generated per cancer type along with dependency scores for the corresponding cellular model. ROC curves were also generated using the average dependency score across all cell lines for a particular cancer model type. The dependency cutoff of &lt; −1 was used to define the active (dependent) class. In breast cancer cell lines, CKI tended to be most predictive of dependency, as the ROC scores generated from the average dependency scores across all breast cancer cell lines in D2, Achilles, and Sanger datasets were 0.98, 0.78, and 0.76, respectively. Overall, we can conclude that the cellular dependency is “fair” to “excellent” at predicting clinical relevance as defined by the CKI (<xref rid="mmc4" ref-type="supplementary-material">Table S3</xref>).</p>
    </sec>
    <sec id="sec2.3">
      <title>Understudied Kinases Are Highly Overexpressed across Multiple Cancer Types</title>
      <p id="p0085">The NIH IDG project research consortium (<ext-link ext-link-type="uri" xlink:href="https://druggablegenome.net/" id="intref0030">https://druggablegenome.net/</ext-link>) has curated a list of “understudied kinases,” which was constructed using a combination of bibliometric and other measures including lack of R01 funding, limited GeneRIF and Gene Ontology (GO) annotation, and lack of available potent and specific chemical probes. These include kinases that bear the TDLs of Tchem, Tbio, and Tdark. Despite being largely ignored by the scientific community, understudied kinases are gaining more attention due to their novelty and therefore opportunities and potential clinical importance.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Of the 151 understudied kinases, 22% are from the “other” group (which includes the subfamilies of <italic>BUB</italic>, <italic>AUR</italic>, and <italic>PLK</italic>), 20.7% are of the CGMC group (which contains MAP kinases and CDKs), and 17.3% are CaMKs. The rest of the understudied kinases include AGC and atypical kinases, with the lowest number of kinases belonging to the well-studied TK and tyrosine kinase-like (TKL) groups (<xref rid="fig2" ref-type="fig">Figures 2</xref>A and 2B).</p>
      <p id="p0090">Since DGE analysis is one of the most effective, scalable, and predictive methods for target prioritization,<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> we proceeded with a comprehensive analysis of the expression patterns of each of the 624 kinases across 20 TCGA cancer types (see <xref rid="sec4" ref-type="sec">STAR Methods</xref> for inclusion criteria). In total, 424 of the 624 kinases studied were found to be significantly differentially overexpressed (adjusted p value &lt; 0.05) in at least two cancers in the TCGA (<xref rid="fig6" ref-type="fig">Figure 6</xref>A; <xref rid="mmc5" ref-type="supplementary-material">Table S4</xref>). <italic>BUB1</italic>, <italic>BUB1B</italic>, and <italic>PLK1</italic> are all significantly overexpressed in every solid cancer analyzed in this study. In addition to being commonly differentially overexpressed, the average log<sub>2</sub>FC between normal and tumor cells is &gt;2 for these kinases. Interestingly, these three kinases all interact with one another in the kinetochore-microtubule spindle assembly checkpoint during mitosis.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> Several other kinases involved in mitosis/cell cycle are overexpressed in the majority of cancers (<italic>AURKA</italic>, <italic>AURKB</italic>, <italic>CDK1</italic>),<xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref> underscoring a hallmark of cancer, cell-cycle dysregulation. Many campaigns are well underway in the pre-clinical and early clinical trial phases to assess the efficacy of targeting such cell-cycle kinases, some with great potential.<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref><sup>,</sup><xref rid="bib46" ref-type="bibr"><sup>46</sup></xref><fig id="fig6"><label>Figure 6</label><caption><p>Four Analyses That Contributed to the CKI</p><p>The x axis contains all kinase names in the analysis, while the y axis represents the TCGA cancer. The plot on the top of the graph shows how many cancers a particular kinase is “significant” in. The plot on the right side of the graph represents how many significant kinases a particular cancer has for this analysis.</p><p>(A) 424 kinases are differentially overexpressed in at least two cancers.</p><p>(B) 317 kinases are prognostic of survival in at least two cancers.</p><p>(C) Many kinases have expressions that correlate with T, N, and M staging. This heat-map quantifies the extent to which each kinase correlates with the clinical outcome, TNM staging (total score out of 3, max score of 1 per parameter)</p><p>(D) 13 kinases have significant hotspot mutations in at least two cancers. See also <xref rid="mmc8" ref-type="supplementary-material">Table S7</xref>.</p></caption><graphic xlink:href="gr6"/></fig></p>
      <p id="p0095">The DGE analysis also included 149 understudied kinases across 20 cancers from the TCGA. In total, 102 understudied kinases were shown to be differentially overexpressed in at least two cancers (<xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>A). In every cancer cohort, the ratio of overexpressed understudied kinases compared to well-studied kinases was nearly 1:1. Several kinase groups appear to be enriched in their overexpression in various cancers. Averaging the log<sub>2</sub>FC of all kinases across all cancers demonstrates that certain kinase transcripts are consistently very highly upregulated. Kinases from the historically understudied CaMK group have the highest average log<sub>2</sub>FC (2.14) (<xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>B). Twenty-four of the 26 understudied CaMKs are overexpressed in at least one cancer. The most commonly overexpressed CaMK is the pseudokinase <italic>CAMKV</italic>, which is significantly upregulated in 14 cancer cohorts. The understudied multi-functional CaMKs (<italic>CAMK1D</italic>, <italic>CAMK1G</italic>, <italic>CAMKK1</italic>, <italic>PNCK</italic>) are overexpressed in 12 cancers, with <italic>PNCK</italic> being overexpressed in 9 alone. <italic>PNCK</italic> (Tbio) mRNA expression and activity has recently been linked to renal cell carcinoma progression and survival,<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> breast cancer tumor microenvironment remodeling,<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> and decreased sensitivity to chemotherapies such as temozolomide.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref>
<italic>PNCK</italic> is highly overexpressed in KIRC (&gt;5 log<sub>2</sub>FC), LUSC (&gt;6 log<sub>2</sub>FC), and LIHC (&gt;6 log<sub>2</sub>FC). In fact, <italic>PNCK</italic> is the most significantly overexpressed kinase in these cancers, suggestive of a tumor-specific differential need for <italic>PNCK</italic> or CaMK activity compared to normal tissue. GTex and other human proteomic/transcriptomic studies show <italic>PNCK</italic> has very low expression levels in normal adult tissue, with the highest expression of mRNA and protein found in the dentate gyrus of the hippocampus. Non-specific CaMK inhibitor KN-93 has been shown in pre-clinical cancer cell models to induce cell-cycle arrest and apoptosis.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> Despite these data, none of the CaMKs are currently targeted by FDA drugs, nor are they being evaluated in clinical or (published) pre-clinical studies.</p>
    </sec>
    <sec id="sec2.4">
      <title>Mutational Hotspots Found in Several Understudied Kinases May Correlate with Overall Survival</title>
      <p id="p0100">Many studies have demonstrated that somatically acquired mutations in kinase domains lead to tumorigenesis and promote cancer progression.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> As mutations accumulate in a precancerous cell, some mutations confer selective advantage through the promotion of tumorigenic functions (such as unchecked cell-cycle progression, immune evasion, invasion, and metastasis), whereas others are effectively neutral “passengers” and are the byproduct of “driver” mutations. The discovery of frequent mutations in various kinase active sites has given rise to a new approach in drug development. Selectively targeting the mutated version of the kinase (versus the wild-type version) has led to great clinical success in oncology. For example, <italic>BRAF</italic> V600E inhibitors have greatly improved survival outcomes in melanoma patients with said mutation.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> Thus, it is important to prioritize kinases with driver mutations as potential novel drug targets. Many cancer genes form mutational hotspots that disrupt their functional domains or active sites, leading to gain- or loss-of-function.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> Therefore, we performed a mutational hotspot analysis on the entire kinome across 20 cancer types for which there were genetic data available. A hotspot mutation is defined as a mutation that occurs in a set of tumor samples significantly more frequently than what is observed by background mutations characterized by genes, cancer types, mutation types, and sequence contexts.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> Hotspot mutations also affect an amino acid position and include missense, nonsense, insertion, and deletion mutations. In total, 42 kinases were found to have significant hotspot mutations, with kinases from the TK family being mutated most frequently. The most commonly mutated kinases were <italic>PIK3CA</italic> (12 cancers), <italic>BRAF</italic> (5 cancers), and <italic>AKT1</italic> (4 cancers), all of which have mutant-targeted inhibitors in clinic or in trial (<xref rid="fig6" ref-type="fig">Figure 6</xref>D; <xref rid="mmc6" ref-type="supplementary-material">Table S5</xref>).<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="bib55" ref-type="bibr"><sup>55</sup></xref><sup>,</sup><xref rid="bib56" ref-type="bibr"><sup>56</sup></xref> Eight understudied kinases were found to have hotspot mutations in at least one cancer (<italic>CDC42BPA</italic>, <italic>DYRK1B</italic>, <italic>DYRK4</italic>, <italic>LMTK3</italic>, <italic>MAPK15</italic>, <italic>NEK7</italic>, <italic>TSSK1B</italic>, and <italic>TTBK1</italic>), with <italic>DYRK4</italic>, <italic>LMTK3</italic>, <italic>MAPK15</italic>, and <italic>NEK7</italic> all having significant hotspot mutations in STAD. Additional study showed that <italic>DYRK1B</italic> was mutated in 4.3% of endometrial carcinoma (UCEC) samples, with significantly worse overall survival for patients harboring the mutated kinase (p &lt; 0.05; <xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>C). Further work must be done to determine which of these kinase mutations are driver mutations and what downstream genomic and transcriptomic effects these mutations have on tumor progression. STAD and COAD were the cancers with the highest kinase mutational burden, with 16 and 11 kinases significantly mutated, respectively. There are currently no first-line treatments for gastric adenocarcinoma that include kinase inhibitors. As a highly heterogeneous disease, genomic data obtained from studies such as this may usher in a new era of personalized medicine for gastric cancer with novel kinase inhibitors against clinically relevant but rarely amplified and mutated kinases.</p>
      <p id="p0105">Comparing our mutational analysis to other pan-cancer TCGA analysis confirms that few kinases are significantly mutated, and few mutations are prognostic of survival. Smith and Sheltzer<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> identified <italic>all</italic> non-silent mutations with &gt;2% frequency and used Cox-proportional hazard analysis to detect genes prognostic of survival. Analysis of their hazard ratios as <italic>Z</italic>-scores does show that Tdark kinase <italic>NRK</italic> is significantly mutated and prognostic in HNSC. Additionally, understudied kinases <italic>CAMK1D</italic>, <italic>PNCK</italic>, and <italic>NEK3</italic> have mutations with significant pan-cancer prognostic value, with <italic>PNCK</italic> being mutated frequently in LUAD and <italic>NEK3</italic> in COAD and READ (p &lt; 0.05; <xref rid="mmc6" ref-type="supplementary-material">Table S5</xref>). Various large-scale mutational analyses of tumors all confirm that the vast majority of somatically acquired mutations are passenger mutations of little or no functional consequence that arise simply as a result of the random mutagenic processes underlying the development of cancer.<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> It is rare, then, that a single kinase is commonly mutated (with the well-known exception, BRAF, which is mutated in over 60% of melanoma cases),<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> suggesting that several infrequently mutated kinases most likely contribute to tumorigenesis and progression.</p>
    </sec>
    <sec id="sec2.5">
      <title>Copy-Number Alterations and Gene Amplifications Are Frequent among Dark Kinases</title>
      <p id="p0110">There are 31 “dark kinases” (Tdark), about which very little information is known. Specifically, these kinases have fewer than 50 antibodies in antibodypedia, fewer than 3 gene RIFs, and a Jensen Lab PubMed text mining score of less than 5.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Tdark kinases are further characterized by poorly defined roles in wider signaling networks, poorly defined function and regulation, poorly defined kinase substrates, lack of activation-loop phospho-antibodies or immunohistochemistry-grade antibodies, and lack of selective chemical tools for functional characterization.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Over a quarter of the dark kinases belong to the “other” group of kinases. Dark kinases are also highly represented among the AGC group (13.3%), atypical kinases (10%), and non-protein “small-molecule kinases” (10%). A number of kinases from the so called “ignorome” <italic>are</italic>, in fact, known to interact with FDA-approved multi-kinase inhibitors. For example, according to DrugCentral data,<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> crizotinib, ruxolitinib, nintedanib, vandetanib, bosutinib, sorafenib, and sunitinib all inhibit understudied kinases in the low nanomolar range (including <italic>SBK3</italic>, <italic>STK32A</italic>, <italic>RIOK1</italic>, <italic>CDK15</italic>, and <italic>CSNK1A1L</italic>), one of which is Tdark (<italic>CSNK1A1L</italic>).<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Thus, it is possible that some therapeutic effect or anti-cancer phenotype can be achieved through inhibition of dark kinases. Homology of kinase ATP binding sites across the kinome and the tendency of many kinase inhibitor chemotypes to inhibit multiple kinases strongly suggests that Tdark kinases can be effectively targeted with small-molecule inhibitors. To promote the pre-clinical study of these dark targets, we must first evaluate and analyze the available clinical data to prioritize the kinases based on several criteria including mutational status, frequency of genetic alteration, and DGE compared to normal samples. If these genomic or transcriptomic variations then correlate with clinical or pathological outcomes, the kinases could be explored in depth as potential oncogenic drivers.</p>
      <p id="p0115">In total, 22 of the dark kinases are significantly overexpressed in at least one TCGA cancer cohort. Increased expression of 15 Tdark kinases correlates with decreased overall survival across multiple cancers (<xref rid="mmc7" ref-type="supplementary-material">Table S6</xref>). For example, high <italic>ADCK5</italic> mRNA levels are a negative prognostic indicator in KIRC, liver hepatocellular carcinoma (LIHC), UCEC, and uveal melanoma (UVM). In breast cancer (BRCA), overexpression of six dark kinases is associated with decreased overall survival (<italic>ALPK3</italic>, <italic>CSNK1A1L</italic>, <italic>CSNK2A3</italic>, <italic>NRK</italic>, <italic>POMK</italic>, and <italic>PSKH1</italic>) (<xref rid="mmc3" ref-type="supplementary-material">Tables S2</xref> and <xref rid="mmc4" ref-type="supplementary-material">S3</xref>). We have also found that many Tdark kinases have altered genetics in the TCGA dataset. Although no Tdark kinases were detected to have significant hotspot mutations, by querying all dark kinases across 9,519 samples in the TCGA (for which copy number alterations [CNA]/copy number variants [CNV] data are available) in 24 cancer cohorts, we found that these genes have significantly altered copy numbers in 36% of patients. <italic>NRBP2</italic>, <italic>POMK</italic>, <italic>ADCK5</italic>, <italic>SCYL3</italic>, <italic>PSKH2</italic>, and <italic>ETNK2</italic> are amplified in over 5%–10% of all patients (<xref rid="mmc6" ref-type="supplementary-material">Table S5</xref>). While CNA and CNVs do not linearly correlate with increases or decreases in mRNA expression, the potential increased expression of many kinases in primary human tumors and their location in focal amplification peaks with other cancer promoting genetic alterations suggests that dark kinases have important functions for the tumor cell phenotype that have not been characterized to date.</p>
      <p id="p0120">It was expected that Tclin kinases would generally score higher on our CKI than other less-characterized proteins. Kinase targets for which there are approved clinical drugs would be assumed to have disease-modifying properties in each cancer, such as effects on survival and tumor progression and size. In BLCA, CHOL, HSNC, KIRC, LUAD, READ, and STAD cohorts, CKI scores were highest for Tclin and MOA-cancer specific targets (TMOA). While this is generally the case for MOA targets (see above), in several cancer cohorts (BRCA, PRAD, COAD, LUSC), Tdark kinases scored higher on the CKI scale than known clinical targets (Tclin) (<xref rid="mmc3" ref-type="supplementary-material">Tables S2</xref> and <xref rid="mmc8" ref-type="supplementary-material">S7</xref>). This suggests that these dark kinases may have similar phenotypic effects on cancer, comparable to well-known targets of approved drugs. Additional analysis of the dark kinome in these cohorts was performed to further explore clinical relevance. Out of 1,108 breast cancer patients, for example, dark kinases are altered in 54% of samples. Overall survival is significantly worse in patients with dark kinase alterations than in those without (p = 4.90e−3). Multiple kinases are commonly amplified including <italic>ADCK5</italic> (14% of samples), <italic>ETNK2</italic> (13%), <italic>NRBP2</italic> (15%), <italic>PSKH2</italic> (12%), <italic>RPS6KC1</italic> (11%), and <italic>SCYL3</italic> (10%). Gene amplification of UCKL1 (6%) and SBK2 (3%) correlated negatively with overall survival and progression-free survival in a KM univariate analysis (p &lt; 0.05; <xref rid="mmc6" ref-type="supplementary-material">Table S5</xref>). Cox-proportional hazard ratios on Tdark kinases and their CNAs reveal that <italic>SBK2</italic>, <italic>ETNK2</italic>, <italic>PSKH2</italic>, <italic>SCYL3</italic>, and <italic>NRBP2</italic> are all significantly prognostic for survival across all cancers.<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> Genes that are amplified in a peak are likely involved in the driving of oncogenic pathways and alterations. <italic>ETNK2</italic> is significantly focally amplified in breast cancer tumors (Q = 7.6e−5) and located in a peak with 94 other genes.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>
<italic>ADCK5</italic>, <italic>ETNK2</italic>, <italic>PSKH2</italic>, <italic>RPS6KC1</italic>, and <italic>SCYL3</italic> are all significantly focally amplified in breast cancer samples as well but are not located in a peak region. Similar trends were confirmed in prostate, lung, and colon cancers (<xref rid="mmc6" ref-type="supplementary-material">Table S5</xref>).</p>
    </sec>
    <sec id="sec2.6">
      <title>CaMKs Are Potential Prognostic Biomarkers</title>
      <p id="p0125">The identification and prioritization of novel biomarkers in cancer can be achieved by the integration of gene expression data with clinical data of patient samples. Genes that are prognostic for various cancers typically have expressions that correlate with overall survival (OS), progression-free survival (PFS), and tumor progression (TNM staging). Despite the abundance of studies exploring the prognostic value of many genes and kinases, very few prognostic biomarkers exist in clinical practice.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> FDA-approved prognostic biomarkers typically include RNA expression panels of multiple genes. It is often true that good prognostic biomarkers may also be drug target candidates if functional characterization of the gene proves as such.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> To assess the potential of utilizing kinase expression as prognostic biomarkers, we aggregated for each kinase, RNA sequencing (RNA-seq), and clinical data from 17 TCGA cancer types and performed KM survival analysis with logrank tests and ANOVA tests between the different tumor stages and grades. Kinases were scored separately for significance in each clinical parameter (TNM staging and histological grade when available; see <xref rid="sec4.3" ref-type="sec">Method Details</xref>).</p>
      <p id="p0130">In our analysis, 357 kinases were shown to be prognostic of M-stage, 522 for N-stage, and 552 for T-stage. In total, 24 of 31 dark kinases showed correlation with TNM staging in at least one cancer (<xref rid="fig6" ref-type="fig">Figure 6</xref>C). The average clinical score per kinase phylogenic group showed significant differences in each cancer cohort (pairwise t test, p &lt; 0.05). The kinases with the highest average clinical scores include <italic>NEK2</italic>, <italic>TRIB3</italic>, <italic>MELK</italic>, <italic>EPHA2</italic>, <italic>SPEG</italic>, and <italic>BRSK1</italic>, several of which are CaMKs. <italic>TRIB3</italic> (Tbio), for example, shows correlation with metastasis in five cancer cohorts. Literature and other studies confirm that this kinase, a member of the CaMK family, may play a role in promoting metastasis in lung and colorectal cancers via induction by the transcription factor NF-kappaB.<xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib63" ref-type="bibr">63</xref> CaMK members <italic>CHEK2</italic>, <italic>TRIB2</italic>, <italic>STK17A</italic>, and <italic>STK17B</italic> are also shown to correlate with TNM staging, further highlighting the potential clinical use for CaMKs as novel cancer targets (<xref rid="mmc8" ref-type="supplementary-material">Table S7</xref>). In total, 317 out of 624 kinases were shown to correlate with survival in at least two cancers (<xref rid="fig6" ref-type="fig">Figure 6</xref>B; <xref rid="mmc7" ref-type="supplementary-material">Table S6</xref>). The kinases with the highest survival scores have been well described in the literature as predictive and prognostic biomarkers in multiple cancers, notably <italic>PGK1</italic>, <italic>PLK1</italic>, and <italic>AURKA</italic>.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref><sup>,</sup><xref rid="bib64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="bib65" ref-type="bibr"><sup>65</sup></xref> Less-studied kinases such as <italic>ALPK3</italic> (Tdark) (<xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>D) and <italic>SPEG</italic> (Tbio) also were shown to correlate with survival in six cancer cohorts (<xref rid="mmc7" ref-type="supplementary-material">Table S6</xref>).</p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Discussion</title>
    <p id="p0135">The typical 20-year-long, multi-billion-dollar drug discovery pipeline all begins with target identification and prioritization.<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref> This is arguably one of the most important steps, as drug failure in the clinic is mostly due to a lack of efficacy or due to toxicities from poor target choice.<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> The use of large-scale omics data has streamlined this process by allowing researchers to combine multiple parameters to evaluate a protein’s potential as a drug target or biomarker. Often, the first glimmer of target potential arises from the analysis of RNA and protein expression in disease tissue compared to healthy tissue. TCGA is one such publicly available database where a breadth of information (transcriptomic, genomic, proteomic, clinical, pathological, and histological) is available for this investigation. An ideal drug target, as described by Bayer,<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref> is one that is first and foremost “druggable” and “assayable”; this is the case for most kinases due to the presence of both a well-defined pocket and ATPase activity. This target will also have an activity that is disease specific (i.e., it is differentially expressed and active in diseased tissue compared to normal tissue). This can be determined preliminarily by DGE analysis and proteomic or phosphoproteomic studies. The target should not be uniformly distributed and expressed throughout the body, a characteristic that can be checked using expression databases such as GTex<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref> or The Human Protein Atlas.<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> Also, immunoprecipitation (IP) is a critical consideration. Therefore, new targets can be attractive, such as “dark” and understudied kinases where there are few or no known small-molecule inhibitors. Finally, and the most difficult parameter to satisfy using informatics alone, kinase targets have to be disease modifying or have a proven function in the pathophysiology of disease. While dysregulation of the kinome as a whole has been indicated in the initiation and progression of nearly every cancer type,<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> disease-modifying kinases must be identified per cancer type using a combination of genetic perturbations and biochemical analyses. Our various analyses, including correlation of CKI with MOA targets clinical studies and cross-validating CKI with experimental datasets such as DepMap,<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> demonstrate that CKI can prioritize drug targets for “disease-modifying” potential, before further target validation studies are pursued. In totality, combining multiple large-scale multi-omics datasets can be a useful first step in prioritizing novel kinase target lists prior to conducting any additional cell-based or animal-based experiments.</p>
    <p id="p0140">In this study, we systematically integrated DGE, KM survival, and mutational hotspot and clinical/pathological correlation analyses in order to prioritize clinically relevant kinase targets across 17 TCGA cancer types. Our clinically focused pan-cancer and pan-kinome analysis highlighted multiple understudied kinases with the potential of promising druggable target opportunities. Moreover, through the development of our accompanying CKI app, which is freely available at <ext-link ext-link-type="uri" xlink:href="http://cki.ccs.miami.edu/" id="intref0035">http://cki.ccs.miami.edu/</ext-link>, we are facilitating the discovery, exploration, and analysis of our data by the scientific community. Our plethora of rich metadata annotations (e.g., TDL, approved MOA, clinical trial status, and kinase phylogenetic and functional classifications) offers researchers a quick and intuitive way to explore the entire kinome and identify understudied kinases with a high therapeutic potential. This app allows a comprehensive view of the kinome based on cancer-type-specific differential expression, survival data, and TNM pathological staging. Researchers can obtain a prioritized list of dark and understudied kinases based on multiple criteria (e.g., cancer type, kinase family). This capability can drive a more efficient drug target prioritization by the research communities. For each dark or understudied kinase, researchers can obtain cancer-type-specific analysis and rank-ordered prioritizations. As more information is discovered and more bioinformatics tools and workflows are available, such as phosphoproteomics and active kinome profiling, the CKI will be updated and optimized to continually enrich the dataset for clinically relevant kinase targets.</p>
    <p id="p0145">All scoring, classifications, normalized data, and statistical analyses are available via the CKI app. To use the app, one can simply select the “Gene” tab and choose a kinase of interest. The CKI scores for each cancer for this kinase will be generated in table form, along with TDL, rank, kinase group and family, and whether or not this kinase has an approved drug MOA. Many annotations from the Drug Target Ontology (DTO)<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> are available as facets to filter and select kinase targets. To start from a disease of interest, one can select a TCGA cancer and the kinase of interest in the “Disease” tab. A kinase table is generated with the specific TCGA cancer and kinase sorted by CKI score. Next, in a sub-tab, a volcano plot will be generated where all differentially expressed genes are displayed. One may click points on the plot to see the specific gene, its count-per-million, and logFC (compared to normal tissue). If the “Study” sub-tab is selected, cancer and gene may be chosen to display boxplots representing mRNA levels for each T, N, and M stage. Finally, if the “Survival” sub-tab is selected, a KM plot is generated for the cancer and gene pair of interest. All data tables may be downloaded via the “Download Data” tab.</p>
    <p id="p0150">Comparing the average CKI scores of “understudied” versus “studied” kinases across all cancers and within individual cancer cohorts suggests that there are many understudied kinases with clinical relevance comparable to currently approved kinase drug targets. The highest-scoring understudied kinase is PKMYT1. PKMYT1 is a member of the WEE1 family of kinases that negatively regulates the G2/M transition of the cell cycle by phosphorylating and inactivating CDK1.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref>
<italic>PKMYT1</italic> is overexpressed in 17 of the 20 cancers analyzed in this study. Cox-regression analysis of <italic>PKMYT1</italic> reveals this kinase is a powerful prognostic and predictive biomarker for survival in KIRC and KIRP cohorts. Other computational work has identified <italic>PKMYT1</italic> as a novel drug target for kidney cancer, using co-expression analysis to reveal <italic>PKMYT1</italic> clusters with other important cell-cycle genes.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref>
<italic>PKMYT1</italic> is classified as Tchem with several active compounds, including PD-0166285, IC<sub>50</sub> = 7 nM and PD-173955, Kd = 44 nM. Although these compounds are not considered chemical probes, they provide starting points for the development of a selective probe or a viable lead compound.</p>
    <p id="p0155">While many of the high-scoring novel kinases are also beginning to be discussed in other studies, many are too “dark” and thus warrant more exploration. Even in large-scale datasets and studies, dark kinases are excluded from the analyses due to a lack of validated antibodies, assays, and chemical probes and a general lack of interest and knowledge of the biology of these targets. A large-scale concerted effort must be taken to effectively bring these “dark” kinases into the light. Such target validation efforts must include RNAi/CRISPR knockdown/knockout cell lines and mice models, elucidation of co-expression and regulatory networks, substrate identification and assay development, development of highly specific chemical probes, and determination of co-crystal structures to facilitate the optimization of lead compounds for future drug development efforts. Much of this work is currently pursued in the IDG project (<ext-link ext-link-type="uri" xlink:href="https://druggablegenome.net/" id="intref0040">https://druggablegenome.net/</ext-link>). The results of this paper will help us, and other groups, select and prioritize their target of choice based on the clinical and biological focus of their own research interests. 2018 was a record year for FDA approvals, yet only 3 of the 39 drugs targeted novel kinase targets and moved TDLs from Tchem to Tclin.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> The rate at which kinase targets move from Tbio or Tdark (little known biology and no potent chemical probes) to Tchem (a small-molecule probe with Kd &lt; 30 nm) is alarmingly slow. No more than 20 IDG targets move from Tbio to Tchem each year, a number encompassing <italic>all</italic> target types (kinases, GPCRs, ion channels). By this pace, it would take decades to wholly illuminate the kinome. Thus, the biases against understudied targets must be lifted, particularly in grant funding, so that there can a full-fledged concerted effort to explore the druggable genome.</p>
    <sec id="sec3.1">
      <title>Limitations of Study</title>
      <p id="p0160">The CKI is a tool for researchers to use to aid the target prioritization or identification process. All data used to generate the index and annotate the kinases have come from large-scale, validated datasets. Target validation, however, requires multi-factorial experiments. Here, we offer a first step in the process and seek to encourage others to follow up in their cellular or animal model of choice to further evaluate understudied kinases as novel drug targets.</p>
    </sec>
  </sec>
  <sec id="sec4">
    <title>STAR★Methods</title>
    <sec id="sec4.1">
      <title>Key Resources Table</title>
      <p id="p0165">
        <table-wrap position="float" id="undtbl1">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th>REAGENT or RESOURCE</th>
                <th>SOURCE</th>
                <th>IDENTIFIER</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td colspan="3">
                  <bold>Software and Algorithms</bold>
                </td>
              </tr>
              <tr>
                <td colspan="3">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td>TCGA data portal</td>
                <td>(Collins, 2007)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/" id="intref0045">https://portal.gdc.cancer.gov/</ext-link>
                </td>
              </tr>
              <tr>
                <td>TCGAbiolinks pipeline</td>
                <td>(Colaprico et al., 2016)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/TCGAbiolinks.html" id="intref0050">https://bioconductor.org/packages/release/bioc/html/TCGAbiolinks.html</ext-link>
                </td>
              </tr>
              <tr>
                <td>R/Bioconductor</td>
                <td>R packages</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://www.bioconductor.org/" id="intref0055">https://www.bioconductor.org/</ext-link>
                </td>
              </tr>
              <tr>
                <td>cBioportal for cancer genomics</td>
                <td>(Cerami et al., 2012; Gao et al., 2013)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/" id="intref0060">https://www.cbioportal.org/</ext-link>
                </td>
              </tr>
              <tr>
                <td>FireHose Broad GDAC</td>
                <td>Broad Institute of MIT &amp; Harvard</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://gdac.broadinstitute.org/" id="intref0065">https://gdac.broadinstitute.org/</ext-link>
                </td>
              </tr>
              <tr>
                <td>recount2</td>
                <td>(Collado-Torres et al., 2017)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/articles/nbt.3838" id="intref0070">http://www.nature.com/articles/nbt.3838</ext-link>
                </td>
              </tr>
              <tr>
                <td>Pharos</td>
                <td>(Nguyen et al., 2017)</td>
                <td>PMID: <ext-link ext-link-type="uri" xlink:href="pmid:27903890" id="intref0075">27903890</ext-link></td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </p>
    </sec>
    <sec id="sec4.2">
      <title>Resource Availability</title>
      <sec id="sec4.2.1">
        <title>Lead Contact</title>
        <p id="p0170">Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Stephan Schürer (<ext-link ext-link-type="uri" xlink:href="mailto:sschurer@med.miami.edu" id="intref0080">sschurer@med.miami.edu</ext-link>)</p>
      </sec>
      <sec id="sec4.2.2">
        <title>Materials Availability</title>
        <p id="p0175">This study did not generate new unique reagents.</p>
      </sec>
      <sec sec-type="data-availability" id="sec4.2.3">
        <title>Data and Code Availability</title>
        <p id="p0180">The published article includes all datasets generated in this study. In addition, data is available for further exploration at the CKI App, <ext-link ext-link-type="uri" xlink:href="https://schurerlab.shinyapps.io/CKIApp/" id="intref0085">https://schurerlab.shinyapps.io/CKIApp/</ext-link>. Code has been deposited to <ext-link ext-link-type="uri" xlink:href="https://github.com/schurerlab/CKI" id="intref0090">https://github.com/schurerlab/CKI</ext-link>.</p>
      </sec>
    </sec>
    <sec id="sec4.3">
      <title>Method Details</title>
      <sec id="sec4.3.1">
        <title>Inclusion Criteria: TCGA Datasets</title>
        <p id="p0185">The TCGA data portal contains the molecular data of over 20,000 tumor and matched normal samples for 33 cancer types from over 11,000 patients (<ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga" id="intref0095">https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga</ext-link>). Our inclusion criteria for kinase analyses were based on the availability of data including normal samples available for differential gene expression analysis, mutational hotspot analysis, clinical data and survival data. First, we only considered solid tumors, thus excluding LAML and DLBC. 9 Cancers (OV, THYM, UVM, SARC, PCPG, UCEC, GBM, UCS and LGG) have been excluded from the complete scoring system due to lack of clinical data (TNM staging). 5 Cancers have only clinical and survival data (ACC, SKCM, PAAD, MESO, and TGCT) but not enough normal samples (&lt; 3 samples) to perform a differential gene expression analysis or mutational analysis. 20 cancers had full gene expression data with normal and tumor samples for DGE analysis. 17 Cancers had the full requirements for scoring for this paper, including clinical and survival data. An overview of the TCGA dataset with number of normal samples, tumor samples and data availability is compiled in the Supplementary material (<xref rid="mmc2" ref-type="supplementary-material">Table S1</xref>). Abbreviations for all the cancer types used in this paper are in accord with the TCGA data portal.</p>
      </sec>
      <sec id="sec4.3.2">
        <title>Inclusion Criteria: Kinases</title>
        <p id="p0190">The complete list of kinases used in this analysis was obtained from Pharos (<ext-link ext-link-type="uri" xlink:href="https://pharos.nih.gov/" id="intref0100">https://pharos.nih.gov/</ext-link>).<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> As of June 2019, 634 kinases were included in our initial analyses; this list contained protein kinases, non-protein kinases and pseudokinases. Several of the kinases annotated in Pharos have different gene names in the TCGA dataset, and needed to be manually curated for our data. Kinase names that could not be mapped to Pharos or whose expression levels were undetectable after expression normalization were excluded from our analyses. Target development levels (TDL) were also obtained from Pharos. Kinases were additionally grouped as “Understudied” or Studied, based off of the IDG designation also available from Pharos. As of June 2019, 151 kinases were annotated as Understudied. However, only 149 of these were included in our analyses (MAP3K21 and STK19 were excluded for above reasons).</p>
        <p id="p0195">Kinases were annotated, per cancer, as MOA targets of approved drugs indicated for the treatment of that specific cancer. For example, while BRAF may have a Tclin annotation, it is not a primary clinical drug target for Breast Cancer (BRCA) treatment. Data for drug target MOA and drug indication was obtained from DrugCentral (<ext-link ext-link-type="uri" xlink:href="https://drugcentral.org/" id="intref0105">https://drugcentral.org/</ext-link>)<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> and “A Comprehensive Map of Molecular Targets”<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref> (<xref rid="mmc3" ref-type="supplementary-material">Table S2</xref>). BLCA was modified to include FGFR1/2/3/4 due to the 2019 approval of Erdafitinib.<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref> Kinase group and family information were obtained from Kinase Drug Target Ontology (DTO) database.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref></p>
        <p id="p0200">Tchem and Tclin kinases were further annotated by clinical trial status using the PKIDB<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> in conjunction with Drug Bank<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> and Drug Central.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> For example, if a kinase target was under a clinical trial investigation, the cancer indication was also mapped to the CKI data (<xref rid="mmc3" ref-type="supplementary-material">Table S2</xref>).</p>
      </sec>
      <sec id="sec4.3.3">
        <title>Data Extraction and Preprocessing</title>
        <p id="p0205">The TCGA data were downloaded from recount2<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref> where TCGA clinical data are also available for all 31 cancers. Differential gene expression analysis was performed for 20 of the 31 cancer types. Datasets with at least three normal (control) samples and three tumor samples were considered, and all other datasets were discarded. For 12 cancers (ACC, LGG, SARC, DLBC, THYM, OV, SKCM, LAML, UVM, PAAD, TGCT, UCS) data were not available for normal samples or were below three normal samples thus preventing the comparison between normal and tumor samples. The data downloaded from recount2 was pre-processed by removing the duplicated TCGA patient IDs or barcodes in each cancer type. Further, the counts were scaled and the lowly expressed genes filtered out using R limma package.<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref> The resultant datasets for each cancer were used for differential expression (DE) analysis, survival analysis, identification of mutational hotspots, and analysis of clinical significance (TNM, pathology, histology).</p>
      </sec>
      <sec id="sec4.3.4">
        <title>Clinical Data</title>
        <p id="p0210">Patient data for AJCC pathological stage<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> and histological grade for each cancer type was obtained from the standardized clinical dataset, the TCGA Pan-Cancer Clinical Data Resource<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref> T,N, and M staging was obtained from the GDC<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref> database using the R/Bioconductor<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> package recount2.<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref> Unique patient IDs were matched using R for each cancer type to include only primary tumor samples for clinical analyses (Sample code “01”). Secondary or metastatic tumors were not considered in this analysis.</p>
      </sec>
      <sec id="sec4.3.5">
        <title>Differential Gene Expression Analysis</title>
        <p id="p0215">For the differential expression analysis, we applied the TCGAbiolinks pipeline on the filtered genes for 20 cancers.<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref> Genes with log<sub>2</sub>FC &gt; 1 and FDR threshold of 0.01 were considered significantly differentially expressed. The significantly differentially expressed genes were mapped to the kinases per cancer. Specifically, only the overexpressed kinases from each cancer type were further considered for the scoring analysis.</p>
      </sec>
      <sec id="sec4.3.6">
        <title>Survival Analysis</title>
        <p id="p0220">In addition to gene expression analysis across cancer samples, survival analysis based on gene expression levels was performed. Available TCGA patient data were used to generate Kaplan-Meier (KM) survival plots. For the plots, patient clinical data was obtained with, i) patient vital status (alive or dead), ii) time (if patient is al then, “days_to_last_follow_up,” if patient is dead then, “days_to_death”), and iii) expression level. Patients with no vital status or follow_up data were considered censored.</p>
        <p id="p0225">For each kinase, the Kaplan-Meier (KM) survival plot was generated across each cancer type, applying the survival R package.<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> The patients were categorized into two distinct groups, high expression (upper quartile) and low expression (lower quartile). The resulted KM survival curves were compared by log-rank test obtaining a P value, which indicates statistical significance of survival samples. Kinases with high expression and significant P value were used for score analysis.</p>
      </sec>
      <sec id="sec4.3.7">
        <title>Mutational Hotspot Analysis</title>
        <p id="p0230">Mutation somatic variants data was obtained from the GDC data portal in the Mutation Annotation Format (MAF) for each cancer type.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> The pre-compiled TCGA MAF objects including somatic mutation along with clinical information were downloaded from the TCGAmutation R package.<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> All Kinases were mapped to each cancer type using R. In addition, the function oncodrive was applied to identify cancer genes (kinase drivers) from a given MAF file.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> Oncodrive is a function based on oncodriveCLUST algorithm, which has been implemented in Python.<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref> For scoring analysis, specifically, only those kinases were selected for each cancer that had a minimum of 5 mutations and significant P values. Kaplan-Meier curves for mutated or amplified kinases were generated using cBioPortal.<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref></p>
      </sec>
      <sec id="sec4.3.8">
        <title>Clinical Analysis</title>
        <p id="p0235">For clinical analysis, Tumor, Node, Metastasis (TNM) staging system developed by American Joint Committee on Cancer AAJC<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref>was used. The TNM system classifies cancer:<list list-type="simple" id="olist0010"><list-item id="o0010"><label>1</label><p id="p0240">T: by the size, which is further grouped into t1- (t1a, t1a1, t1b, t1b1), t2- (t2a, t2a1, t2a2, t2b, t2c), t3- (t3a, t3b, t3c) and t4- (t4a, t4b, t4c, t4d, t4e).</p></list-item><list-item id="o0015"><label>2</label><p id="p0245">N: involvement of regional lymph nodes, subtypes n0, n1- (n1a, n1b, n1c, n1mi), n2- (n2a, n2c, n3a) and n3 - (n3a, n3b, n3c).</p></list-item><list-item id="o0020"><label>3</label><p id="p0250">M: presence or absence of distant metastasis, sub divided into m0 and m1.</p></list-item></list></p>
        <p id="p0255">We used ANOVA to identify significant differences between t1-t4 for each of the four metrics. Subsequently, ANOVA was also performed for N and M to see if there are any significant changes between n0-n3 and m0-m1. In addition, the histological grade was also considered for scoring. The grade is a qualitative assessment for differentiated cells under microscope. The differentiated cells are low grade (g1, g2) and dysmorphic and de-differentiated cells are considered high grade (g3, g4). The statistical significance differences between histological grade g1-g4 was calculated using ANOVA.</p>
      </sec>
      <sec id="sec4.3.9">
        <title>Scoring</title>
        <p id="p0260">We have developed the Clinical Kinase Index (CKI) to evaluate the prognostic and clinical value of the mRNA expression levels of each kinase in the human kinome. RNASeq data obtained from normal and solid-tumor samples was used to correlate RPKM with advanced tumor staging in clinical, pathological and histological classifications. Since we are mostly interested in the understudied kinome, we opted to not include RPPA or protein expression data since this was unavailable due to lack of specific and validated antibodies for such kinases. Additionally, we recognize that levels of messenger RNA do not necessarily correlate linearly with kinase activity<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> and a future study of the phospho-kinome would offer more insight into effects these kinases have on cancer progression.</p>
        <p id="p0265">The Clinical Kinase Index (CKI) score was generated for each kinase per cancer using 4 parameters: Differential Gene Overexpression, Overall Survival (OS), Mutational Hotspots and Clinical/Pathological Progression. If the kinase was shown to be significantly overexpressed, correlated with negative survival outcomes or significantly mutated, it received a score of 1 (per parameter). A Clinical score was created using an average per each clinical/pathological parameter which include clinical stage, T, N and M staging, and histological staging/grade. For example, ANOVA analysis was used to determine significant differences in the means of expression for each kinase in each T stage (t1 versus t2, t2 versus t3 etc.). If a kinase expression was significantly increased between two T stages, it received a score of 1. If it was significant between multiple T stages, the scores were averaged to have a maximum score of 1. This was repeated for M and N stages as well as other clinical parameters including histological grade, pathological stage and clinical stage. The total clinical score was a sum of these scores, with a maximum score varying per cancer due the differing availability of clinical and pathological data in the TCGA datasets. Final scores were determined by summing all parameters and dividing by the maximum possible score and multiplying by 100% to normalize across all cancer cohorts. In short, a score is only assigned to a kinase if its increased expression correlates with a progression in staging, a decrease in survival or has significant mutations.</p>
      </sec>
      <sec id="sec4.3.10">
        <title>Clinical Kinase Index (CKI) Web Application (<ext-link ext-link-type="uri" xlink:href="https://schurerlab.shinyapps.io/CKIApp/" id="intref0110">https://schurerlab.shinyapps.io/CKIApp/</ext-link>)</title>
        <p id="p0270">The Clinical Kinase Index and application was developed and written in R language R 3.3 or higher using the R packages: shiny, RColorBrewer, gplots, plyr, ggplot2, limma, TCGAbiolinks, tidyverse, recount2, edgeR, SummarizedExperiment, devtools, superheat, xlsx, survival, RTCGA.rnaseq, RTCGA.clinical, survminer, maftools, corrplot, colorRamp, and plotly. The construction of the App utilizes Shiny, a framework to build and deploy interactive Web applications in R. The data have been processed using the R Bioconductor databases and packages included within other requirements. The CKI homepage includes the mRNA expression heatmaps of all kinases (and understudied kinases). The application includes a table which can be filtered based off of user input and contains the kinase gene name, cancer of interest, clinical kinase index score, ranking and other meta-data annotations for the target. Through the gene page users can explore the score of a particular kinases of interest taking advantage of all the information available for specific dataset, which can be filtered: TDL, Kinase type, Kinase Group, MOA targets. Additionally, the CKI disease page allows users to generate 1) a table with specific cancer of interest and filter by TDL and understudied kinases. It also develops a plot of particular cancer including 2) Volcano plots to display differentially expressed kinases per cancer. Next, the clinical Data page produces different plots of particular cancer and gene of interest including 1) Boxplots showing the expression of kinases according to TNM staging, and 2) Kaplan Meier curve representing the overall survival levels of each gene per cancer. The data to reproduce the plots can be downloaded on the Download page for future analysis. This includes some data that has not been visualized in the app, such as mutational and CNA analyses. Code is available on GitHub <ext-link ext-link-type="uri" xlink:href="https://github.com/schurerlab/CKI" id="intref0115">https://github.com/schurerlab/CKI</ext-link>.</p>
      </sec>
      <sec id="sec4.3.11">
        <title>DepMap Analysis</title>
        <p id="p0275">Data was downloaded from DepMap Portal.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> The datasets used were CRISPR (Avana) Public 19Q2, Sanger CRISPR and Combined RNAi, along with the cell line metadata. Using DepMap Cell line metadata, cell lines were extracted using “disease” and “disease subtype” terms to match the corresponding TCGA cohort. Genes were manually annotated as “dependent” for our analyses if the dependency score was less than −1.</p>
      </sec>
      <sec id="sec4.3.12">
        <title>External Tools</title>
        <p id="p0280">Gene amplification data was obtained from cBioPortal using all TCGA Provisional Datasets. Focal amplifications were identified using the GISTIC tool from the BROAD Institute.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> Gene Set Enrichment Analysis was performed using MSigDB.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> The top 25% scoring kinases for each cancer were used as input. Positional Gene Sets, chemical and genetic perturbations, canonical pathways, KEGG gene sets, cancer modules and oncogenic signatures were selected for analysis. The FDR q-value threshold was 0.05 and the top 100 enriched gene sets were saved.</p>
      </sec>
    </sec>
    <sec id="sec4.4">
      <title>Quantification and Statistical Analysis</title>
      <p id="p0285">Statistical analyses used are outlined in the paper. Statistical significance was broadly defined as having a p value &lt; 0.05 unless otherwise stated. All reported statistical analyses are available in the supplemental tables with associated p values and adjusted p values.</p>
    </sec>
    <sec id="sec4.5">
      <title>Additional Resources</title>
      <p id="p0290">For further analysis and graphical display of the data generated in this study, the Clinical Kinase Index (CKI) app is available for use: <ext-link ext-link-type="uri" xlink:href="https://schurerlab.shinyapps.io/CKIApp" id="intref0120">https://schurerlab.shinyapps.io/CKIApp</ext-link>.</p>
    </sec>
  </sec>
</body>
<back>
  <ref-list id="cebib0010">
    <title>References</title>
    <ref id="bib1">
      <label>1</label>
      <element-citation publication-type="journal" id="sref1">
        <person-group person-group-type="author">
          <name>
            <surname>Ursu</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Holmes</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Knockel</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Bologa</surname>
            <given-names>C.G.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>J.J.</given-names>
          </name>
          <name>
            <surname>Mathias</surname>
            <given-names>S.L.</given-names>
          </name>
          <name>
            <surname>Nelson</surname>
            <given-names>S.J.</given-names>
          </name>
          <name>
            <surname>Oprea</surname>
            <given-names>T.I.</given-names>
          </name>
        </person-group>
        <article-title>DrugCentral: online drug compendium</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>45</volume>
        <year>2017</year>
        <fpage>D932</fpage>
        <lpage>D939</lpage>
        <pub-id pub-id-type="pmid">27789690</pub-id>
      </element-citation>
    </ref>
    <ref id="bib2">
      <label>2</label>
      <element-citation publication-type="journal" id="sref2">
        <person-group person-group-type="author">
          <name>
            <surname>Ursu</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Glick</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Oprea</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Novel drug targets in 2018</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <year>2019</year>
        <pub-id pub-id-type="doi">10.1038/d41573-019-00052-5</pub-id>
        <comment>Published online March 26, 2019</comment>
      </element-citation>
    </ref>
    <ref id="bib3">
      <label>3</label>
      <element-citation publication-type="journal" id="sref3">
        <person-group person-group-type="author">
          <name>
            <surname>Ursu</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Holmes</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Bologa</surname>
            <given-names>C.G.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>J.J.</given-names>
          </name>
          <name>
            <surname>Mathias</surname>
            <given-names>S.L.</given-names>
          </name>
          <name>
            <surname>Stathias</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>D.T.</given-names>
          </name>
          <name>
            <surname>Schürer</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Oprea</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>DrugCentral 2018: an update</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>47</volume>
        <year>2019</year>
        <fpage>D963</fpage>
        <lpage>D970</lpage>
        <pub-id pub-id-type="pmid">30371892</pub-id>
      </element-citation>
    </ref>
    <ref id="bib4">
      <label>4</label>
      <element-citation publication-type="journal" id="sref4">
        <person-group person-group-type="author">
          <name>
            <surname>Wallerand</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Robert</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Bernhard</surname>
            <given-names>J.C.</given-names>
          </name>
          <name>
            <surname>Ravaud</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Patard</surname>
            <given-names>J.J.</given-names>
          </name>
        </person-group>
        <article-title>Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer</article-title>
        <source>Arch. Esp. Urol.</source>
        <volume>63</volume>
        <year>2010</year>
        <fpage>773</fpage>
        <lpage>787</lpage>
        <pub-id pub-id-type="pmid">21098902</pub-id>
      </element-citation>
    </ref>
    <ref id="bib5">
      <label>5</label>
      <element-citation publication-type="journal" id="sref5">
        <person-group person-group-type="author">
          <name>
            <surname>Vincenzi</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Imperatori</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Silletta</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Marrucci</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Santini</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Tonini</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>Emerging kinase inhibitors of the treatment of gastric cancer</article-title>
        <source>Expert Opin. Emerg. Drugs</source>
        <volume>20</volume>
        <year>2015</year>
        <fpage>479</fpage>
        <lpage>493</lpage>
        <pub-id pub-id-type="pmid">26021342</pub-id>
      </element-citation>
    </ref>
    <ref id="bib6">
      <label>6</label>
      <element-citation publication-type="journal" id="sref6">
        <person-group person-group-type="author">
          <name>
            <surname>Petrylak</surname>
            <given-names>D.P.</given-names>
          </name>
          <name>
            <surname>Tangen</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Van Veldhuizen</surname>
            <given-names>P.J.</given-names>
            <suffix>Jr.</suffix>
          </name>
          <name>
            <surname>Goodwin</surname>
            <given-names>J.W.</given-names>
          </name>
          <name>
            <surname>Twardowski</surname>
            <given-names>P.W.</given-names>
          </name>
          <name>
            <surname>Atkins</surname>
            <given-names>J.N.</given-names>
          </name>
          <name>
            <surname>Kakhil</surname>
            <given-names>S.R.</given-names>
          </name>
          <name>
            <surname>Lange</surname>
            <given-names>M.K.</given-names>
          </name>
          <name>
            <surname>Mansukhani</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Crawford</surname>
            <given-names>E.D.</given-names>
          </name>
        </person-group>
        <article-title>Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium</article-title>
        <source>BJU Int.</source>
        <volume>105</volume>
        <year>2010</year>
        <fpage>317</fpage>
        <lpage>321</lpage>
        <pub-id pub-id-type="pmid">19888985</pub-id>
      </element-citation>
    </ref>
    <ref id="bib7">
      <label>7</label>
      <element-citation publication-type="journal" id="sref7">
        <person-group person-group-type="author">
          <name>
            <surname>Morishita</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Gong</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Masaki</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Targeting receptor tyrosine kinases in gastric cancer</article-title>
        <source>World J. Gastroenterol.</source>
        <volume>20</volume>
        <year>2014</year>
        <fpage>4536</fpage>
        <lpage>4545</lpage>
        <pub-id pub-id-type="pmid">24782606</pub-id>
      </element-citation>
    </ref>
    <ref id="bib8">
      <label>8</label>
      <element-citation publication-type="journal" id="sref8">
        <person-group person-group-type="author">
          <name>
            <surname>Westphal</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Maire</surname>
            <given-names>C.L.</given-names>
          </name>
          <name>
            <surname>Lamszus</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise</article-title>
        <source>CNS Drugs</source>
        <volume>31</volume>
        <year>2017</year>
        <fpage>723</fpage>
        <lpage>735</lpage>
        <pub-id pub-id-type="pmid">28791656</pub-id>
      </element-citation>
    </ref>
    <ref id="bib9">
      <label>9</label>
      <element-citation publication-type="journal" id="sref9">
        <person-group person-group-type="author">
          <name>
            <surname>Kruck</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Bedke</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Hennenlotter</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Ohneseit</surname>
            <given-names>P.A.</given-names>
          </name>
          <name>
            <surname>Kuehs</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Senger</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Sievert</surname>
            <given-names>K.D.</given-names>
          </name>
          <name>
            <surname>Stenzl</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression</article-title>
        <source>Oncol. Rep.</source>
        <volume>23</volume>
        <year>2010</year>
        <fpage>159</fpage>
        <lpage>163</lpage>
        <pub-id pub-id-type="pmid">19956876</pub-id>
      </element-citation>
    </ref>
    <ref id="bib10">
      <label>10</label>
      <element-citation publication-type="journal" id="sref10">
        <person-group person-group-type="author">
          <name>
            <surname>Oprea</surname>
            <given-names>T.I.</given-names>
          </name>
          <name>
            <surname>Bologa</surname>
            <given-names>C.G.</given-names>
          </name>
          <name>
            <surname>Brunak</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Gan</surname>
            <given-names>G.N.</given-names>
          </name>
          <name>
            <surname>Gaulton</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Gomez</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Guha</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Hersey</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Holmes</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Unexplored therapeutic opportunities in the human genome</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <volume>17</volume>
        <year>2018</year>
        <fpage>377</fpage>
      </element-citation>
    </ref>
    <ref id="bib11">
      <label>11</label>
      <element-citation publication-type="journal" id="sref11">
        <person-group person-group-type="author">
          <name>
            <surname>Nguyen</surname>
            <given-names>D.T.</given-names>
          </name>
          <name>
            <surname>Mathias</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Bologa</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Brunak</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Fernandez</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Gaulton</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Hersey</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Holmes</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>L.J.</given-names>
          </name>
          <name>
            <surname>Karlsson</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Pharos: Collating protein information to shed light on the druggable genome</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>45</volume>
        <year>2017</year>
        <fpage>D995</fpage>
        <lpage>D1002</lpage>
        <pub-id pub-id-type="pmid">27903890</pub-id>
      </element-citation>
    </ref>
    <ref id="bib12">
      <label>12</label>
      <element-citation publication-type="journal" id="sref12">
        <person-group person-group-type="author">
          <name>
            <surname>Wishart</surname>
            <given-names>D.S.</given-names>
          </name>
          <name>
            <surname>Knox</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>A.C.</given-names>
          </name>
          <name>
            <surname>Shrivastava</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Hassanali</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Stothard</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Woolsey</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>DrugBank: a comprehensive resource for in silico drug discovery and exploration</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>34</volume>
        <year>2006</year>
        <fpage>D668</fpage>
        <lpage>D672</lpage>
        <pub-id pub-id-type="pmid">16381955</pub-id>
      </element-citation>
    </ref>
    <ref id="bib13">
      <label>13</label>
      <element-citation publication-type="journal" id="sref13">
        <person-group person-group-type="author">
          <name>
            <surname>Carles</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Bourg</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Bonnet</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials</article-title>
        <source>Molecules</source>
        <volume>23</volume>
        <year>2018</year>
        <fpage>E908</fpage>
        <pub-id pub-id-type="pmid">29662024</pub-id>
      </element-citation>
    </ref>
    <ref id="bib14">
      <label>14</label>
      <element-citation publication-type="journal" id="sref14">
        <person-group person-group-type="author">
          <name>
            <surname>Axtman</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Drewry</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Wells</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>CDK16: the pick of the understudied PCTAIRE kinases</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <volume>18</volume>
        <year>2019</year>
        <fpage>489</fpage>
        <pub-id pub-id-type="pmid">31267068</pub-id>
      </element-citation>
    </ref>
    <ref id="bib15">
      <label>15</label>
      <element-citation publication-type="journal" id="sref15">
        <person-group person-group-type="author">
          <name>
            <surname>Asquith</surname>
            <given-names>C.R.M.</given-names>
          </name>
          <name>
            <surname>East</surname>
            <given-names>M.P.</given-names>
          </name>
          <name>
            <surname>Zuercher</surname>
            <given-names>W.J.</given-names>
          </name>
        </person-group>
        <article-title>RIOK2: straddling the kinase/ATPase line</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <year>2019</year>
        <pub-id pub-id-type="doi">10.1038/d41573-019-00107-7</pub-id>
        <comment>Published online July 1, 2019</comment>
      </element-citation>
    </ref>
    <ref id="bib16">
      <label>16</label>
      <element-citation publication-type="journal" id="sref16">
        <person-group person-group-type="author">
          <name>
            <surname>Belinky</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Nativ</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Stelzer</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Zimmerman</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Iny Stein</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Safran</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Lancet</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>PathCards: multi-source consolidation of human biological pathways</article-title>
        <source>Database (Oxford)</source>
        <volume>2015</volume>
        <year>2015</year>
        <fpage>bav006</fpage>
        <pub-id pub-id-type="pmid">25725062</pub-id>
      </element-citation>
    </ref>
    <ref id="bib17">
      <label>17</label>
      <element-citation publication-type="journal" id="sref17">
        <person-group person-group-type="author">
          <name>
            <surname>Lin</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Mehta</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Küçük-McGinty</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Turner</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Vidovic</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Forlin</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Koleti</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>D.T.</given-names>
          </name>
          <name>
            <surname>Jensen</surname>
            <given-names>L.J.</given-names>
          </name>
          <name>
            <surname>Guha</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Drug target ontology to classify and integrate drug discovery data</article-title>
        <source>J. Biomed. Semantics</source>
        <volume>8</volume>
        <year>2017</year>
        <fpage>50</fpage>
        <pub-id pub-id-type="pmid">29122012</pub-id>
      </element-citation>
    </ref>
    <ref id="bib18">
      <label>18</label>
      <element-citation publication-type="journal" id="sref18">
        <person-group person-group-type="author">
          <name>
            <surname>Stathias</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Jermakowicz</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Maloof</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Forlin</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Walters</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Suter</surname>
            <given-names>R.K.</given-names>
          </name>
          <name>
            <surname>Durante</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Williams</surname>
            <given-names>S.L.</given-names>
          </name>
          <name>
            <surname>Harbour</surname>
            <given-names>J.W.</given-names>
          </name>
          <name>
            <surname>Volmar</surname>
            <given-names>C.H.</given-names>
          </name>
        </person-group>
        <article-title>Drug and disease signature integration identifies synergistic combinations in glioblastoma</article-title>
        <source>Nat. Commun.</source>
        <volume>9</volume>
        <year>2018</year>
        <fpage>5315</fpage>
        <pub-id pub-id-type="pmid">30552330</pub-id>
      </element-citation>
    </ref>
    <ref id="bib19">
      <label>19</label>
      <element-citation publication-type="journal" id="sref19">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Kovács</surname>
            <given-names>I.A.</given-names>
          </name>
          <name>
            <surname>Barabási</surname>
            <given-names>A.L.</given-names>
          </name>
        </person-group>
        <article-title>Publisher Correction: Network-based prediction of drug combinations</article-title>
        <source>Nat. Commun.</source>
        <volume>10</volume>
        <year>2019</year>
        <fpage>1806</fpage>
        <pub-id pub-id-type="pmid">30988295</pub-id>
      </element-citation>
    </ref>
    <ref id="bib20">
      <label>20</label>
      <element-citation publication-type="journal" id="sref20">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>C.T.</given-names>
          </name>
          <name>
            <surname>Hsieh</surname>
            <given-names>C.H.</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>Y.H.</given-names>
          </name>
          <name>
            <surname>Oyang</surname>
            <given-names>Y.J.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>H.C.</given-names>
          </name>
          <name>
            <surname>Juan</surname>
            <given-names>H.F.</given-names>
          </name>
        </person-group>
        <article-title>Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery</article-title>
        <source>iScience</source>
        <volume>15</volume>
        <year>2019</year>
        <fpage>291</fpage>
        <lpage>306</lpage>
        <pub-id pub-id-type="pmid">31102995</pub-id>
      </element-citation>
    </ref>
    <ref id="bib21">
      <label>21</label>
      <element-citation publication-type="journal" id="sref21">
        <person-group person-group-type="author">
          <name>
            <surname>Nussinov</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Tsai</surname>
            <given-names>C.J.</given-names>
          </name>
          <name>
            <surname>Jang</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>A New View of Pathway-Driven Drug Resistance in Tumor Proliferation</article-title>
        <source>Trends Pharmacol. Sci.</source>
        <volume>38</volume>
        <year>2017</year>
        <fpage>427</fpage>
        <lpage>437</lpage>
        <pub-id pub-id-type="pmid">28245913</pub-id>
      </element-citation>
    </ref>
    <ref id="bib22">
      <label>22</label>
      <element-citation publication-type="journal" id="sref22">
        <person-group person-group-type="author">
          <name>
            <surname>Stuhlmiller</surname>
            <given-names>T.J.</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Zawistowski</surname>
            <given-names>J.S.</given-names>
          </name>
          <name>
            <surname>Nakamura</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Beltran</surname>
            <given-names>A.S.</given-names>
          </name>
          <name>
            <surname>Duncan</surname>
            <given-names>J.S.</given-names>
          </name>
          <name>
            <surname>Angus</surname>
            <given-names>S.P.</given-names>
          </name>
          <name>
            <surname>Collins</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Granger</surname>
            <given-names>D.A.</given-names>
          </name>
          <name>
            <surname>Reuther</surname>
            <given-names>R.A.</given-names>
          </name>
        </person-group>
        <article-title>Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains</article-title>
        <source>Cell Rep.</source>
        <volume>11</volume>
        <year>2015</year>
        <fpage>390</fpage>
        <lpage>404</lpage>
        <pub-id pub-id-type="pmid">25865888</pub-id>
      </element-citation>
    </ref>
    <ref id="bib23">
      <label>23</label>
      <element-citation publication-type="journal" id="sref23">
        <person-group person-group-type="author">
          <name>
            <surname>Regan Anderson</surname>
            <given-names>T.M.</given-names>
          </name>
          <name>
            <surname>Peacock</surname>
            <given-names>D.L.</given-names>
          </name>
          <name>
            <surname>Daniel</surname>
            <given-names>A.R.</given-names>
          </name>
          <name>
            <surname>Hubbard</surname>
            <given-names>G.K.</given-names>
          </name>
          <name>
            <surname>Lofgren</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Girard</surname>
            <given-names>B.J.</given-names>
          </name>
          <name>
            <surname>Schörg</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Hoogewijs</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Wenger</surname>
            <given-names>R.H.</given-names>
          </name>
          <name>
            <surname>Seagroves</surname>
            <given-names>T.N.</given-names>
          </name>
          <name>
            <surname>Lange</surname>
            <given-names>C.A.</given-names>
          </name>
        </person-group>
        <article-title>Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression</article-title>
        <source>Cancer Res.</source>
        <volume>73</volume>
        <year>2013</year>
        <fpage>5810</fpage>
        <lpage>5820</lpage>
        <pub-id pub-id-type="pmid">23928995</pub-id>
      </element-citation>
    </ref>
    <ref id="bib24">
      <label>24</label>
      <element-citation publication-type="journal" id="sref24">
        <person-group person-group-type="author">
          <name>
            <surname>Xiang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Chatti</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Qiu</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Lakshmi</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Krasnitz</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Hicks</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>W.T.</given-names>
          </name>
          <name>
            <surname>Muthuswamy</surname>
            <given-names>S.K.</given-names>
          </name>
        </person-group>
        <article-title>Brk is coamplified with ErbB2 to promote proliferation in breast cancer</article-title>
        <source>Proc. Natl. Acad. Sci. USA</source>
        <volume>105</volume>
        <year>2008</year>
        <fpage>12463</fpage>
        <lpage>12468</lpage>
        <pub-id pub-id-type="pmid">18719096</pub-id>
      </element-citation>
    </ref>
    <ref id="bib25">
      <label>25</label>
      <element-citation publication-type="journal" id="sref25">
        <person-group person-group-type="author">
          <name>
            <surname>Harvey</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Crompton</surname>
            <given-names>M.R.</given-names>
          </name>
        </person-group>
        <article-title>Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation</article-title>
        <source>Oncogene</source>
        <volume>22</volume>
        <year>2003</year>
        <fpage>5006</fpage>
        <lpage>5010</lpage>
        <pub-id pub-id-type="pmid">12902983</pub-id>
      </element-citation>
    </ref>
    <ref id="bib26">
      <label>26</label>
      <element-citation publication-type="journal" id="sref26">
        <person-group person-group-type="author">
          <name>
            <surname>Paez</surname>
            <given-names>J.G.</given-names>
          </name>
          <name>
            <surname>Jänne</surname>
            <given-names>P.A.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>J.C.</given-names>
          </name>
          <name>
            <surname>Tracy</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Greulich</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Gabriel</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Herman</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Kaye</surname>
            <given-names>F.J.</given-names>
          </name>
          <name>
            <surname>Lindeman</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Boggon</surname>
            <given-names>T.J.</given-names>
          </name>
        </person-group>
        <article-title>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</article-title>
        <source>Science</source>
        <volume>304</volume>
        <year>2004</year>
        <fpage>1497</fpage>
        <lpage>1500</lpage>
        <pub-id pub-id-type="pmid">15118125</pub-id>
      </element-citation>
    </ref>
    <ref id="bib27">
      <label>27</label>
      <element-citation publication-type="journal" id="sref27">
        <person-group person-group-type="author">
          <name>
            <surname>Ladanyi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Pao</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond</article-title>
        <source>Mod. Pathol.</source>
        <volume>21</volume>
        <year>2008</year>
        <fpage>S16</fpage>
        <lpage>S22</lpage>
        <pub-id pub-id-type="pmid">18437168</pub-id>
      </element-citation>
    </ref>
    <ref id="bib28">
      <label>28</label>
      <element-citation publication-type="journal" id="sref28">
        <person-group person-group-type="author">
          <name>
            <surname>Stinchcombe</surname>
            <given-names>T.E.</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>G.L.</given-names>
          </name>
        </person-group>
        <article-title>MEK inhibition in non-small cell lung cancer</article-title>
        <source>Lung Cancer</source>
        <volume>86</volume>
        <year>2014</year>
        <fpage>121</fpage>
        <lpage>125</lpage>
        <pub-id pub-id-type="pmid">25257766</pub-id>
      </element-citation>
    </ref>
    <ref id="bib29">
      <label>29</label>
      <element-citation publication-type="journal" id="sref29">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Giaccone</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>MEK inhibitors under development for treatment of non-small-cell lung cancer</article-title>
        <source>Expert Opin. Investig. Drugs</source>
        <volume>27</volume>
        <year>2018</year>
        <fpage>17</fpage>
        <lpage>30</lpage>
      </element-citation>
    </ref>
    <ref id="bib30">
      <label>30</label>
      <element-citation publication-type="journal" id="sref30">
        <person-group person-group-type="author">
          <name>
            <surname>Gutteridge</surname>
            <given-names>R.E.</given-names>
          </name>
          <name>
            <surname>Ndiaye</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Ahmad</surname>
            <given-names>N.</given-names>
          </name>
        </person-group>
        <article-title>Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics</article-title>
        <source>Mol. Cancer Ther.</source>
        <volume>15</volume>
        <year>2016</year>
        <fpage>1427</fpage>
        <lpage>1435</lpage>
        <pub-id pub-id-type="pmid">27330107</pub-id>
      </element-citation>
    </ref>
    <ref id="bib31">
      <label>31</label>
      <element-citation publication-type="journal" id="sref31">
        <person-group person-group-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Farzan</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Ali</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Buluwela</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Saurin</surname>
            <given-names>A.T.</given-names>
          </name>
          <name>
            <surname>Meek</surname>
            <given-names>D.W.</given-names>
          </name>
        </person-group>
        <article-title>The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation</article-title>
        <source>Sci. Rep.</source>
        <volume>7</volume>
        <year>2017</year>
        <fpage>16115</fpage>
        <pub-id pub-id-type="pmid">29170437</pub-id>
      </element-citation>
    </ref>
    <ref id="bib32">
      <label>32</label>
      <element-citation publication-type="journal" id="sref32">
        <person-group person-group-type="author">
          <name>
            <surname>Oikawa</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Kitamura</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Kinjo</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Iwawaki</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Direct association of unfolded proteins with mammalian ER stress sensor, IRE1β</article-title>
        <source>PLoS ONE</source>
        <volume>7</volume>
        <year>2012</year>
        <fpage>e51290</fpage>
        <pub-id pub-id-type="pmid">23236464</pub-id>
      </element-citation>
    </ref>
    <ref id="bib33">
      <label>33</label>
      <element-citation publication-type="journal" id="sref33">
        <person-group person-group-type="author">
          <name>
            <surname>Madden</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Logue</surname>
            <given-names>S.E.</given-names>
          </name>
          <name>
            <surname>Healy</surname>
            <given-names>S.J.</given-names>
          </name>
          <name>
            <surname>Manie</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Samali</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>The role of the unfolded protein response in cancer progression: From oncogenesis to chemoresistance</article-title>
        <source>Biol. Cell</source>
        <volume>111</volume>
        <year>2019</year>
        <fpage>1</fpage>
        <lpage>17</lpage>
        <pub-id pub-id-type="pmid">30302777</pub-id>
      </element-citation>
    </ref>
    <ref id="bib34">
      <label>34</label>
      <element-citation publication-type="journal" id="sref34">
        <person-group person-group-type="author">
          <name>
            <surname>Liberzon</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Subramanian</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Pinchback</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Thorvaldsdóttir</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Tamayo</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Mesirov</surname>
            <given-names>J.P.</given-names>
          </name>
        </person-group>
        <article-title>Molecular signatures database (MSigDB) 3.0</article-title>
        <source>Bioinformatics</source>
        <volume>27</volume>
        <year>2011</year>
        <fpage>1739</fpage>
        <lpage>1740</lpage>
        <pub-id pub-id-type="pmid">21546393</pub-id>
      </element-citation>
    </ref>
    <ref id="bib35">
      <label>35</label>
      <element-citation publication-type="journal" id="sref35">
        <person-group person-group-type="author">
          <name>
            <surname>Liberzon</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Birger</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Thorvaldsdóttir</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Ghandi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Mesirov</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Tamayo</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title>
        <source>Cell Syst.</source>
        <volume>1</volume>
        <year>2015</year>
        <fpage>417</fpage>
        <lpage>425</lpage>
        <pub-id pub-id-type="pmid">26771021</pub-id>
      </element-citation>
    </ref>
    <ref id="bib36">
      <label>36</label>
      <element-citation publication-type="journal" id="sref36">
        <person-group person-group-type="author">
          <name>
            <surname>Tsherniak</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Vazquez</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Montgomery</surname>
            <given-names>P.G.</given-names>
          </name>
          <name>
            <surname>Weir</surname>
            <given-names>B.A.</given-names>
          </name>
          <name>
            <surname>Kryukov</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Cowley</surname>
            <given-names>G.S.</given-names>
          </name>
          <name>
            <surname>Gill</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Harrington</surname>
            <given-names>W.F.</given-names>
          </name>
          <name>
            <surname>Pantel</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Krill-Burger</surname>
            <given-names>J.M.</given-names>
          </name>
        </person-group>
        <article-title>Defining a Cancer Dependency Map</article-title>
        <source>Cell</source>
        <volume>170</volume>
        <year>2017</year>
        <fpage>564</fpage>
        <lpage>576.e16</lpage>
        <pub-id pub-id-type="pmid">28753430</pub-id>
      </element-citation>
    </ref>
    <ref id="bib37">
      <label>37</label>
      <element-citation publication-type="journal" id="sref37">
        <person-group person-group-type="author">
          <name>
            <surname>Iorio</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Knijnenburg</surname>
            <given-names>T.A.</given-names>
          </name>
          <name>
            <surname>Vis</surname>
            <given-names>D.J.</given-names>
          </name>
          <name>
            <surname>Bignell</surname>
            <given-names>G.R.</given-names>
          </name>
          <name>
            <surname>Menden</surname>
            <given-names>M.P.</given-names>
          </name>
          <name>
            <surname>Schubert</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Aben</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Gonçalves</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Barthorpe</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Lightfoot</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>A Landscape of Pharmacogenomic Interactions in Cancer</article-title>
        <source>Cell</source>
        <volume>166</volume>
        <year>2016</year>
        <fpage>740</fpage>
        <lpage>754</lpage>
        <pub-id pub-id-type="pmid">27397505</pub-id>
      </element-citation>
    </ref>
    <ref id="bib38">
      <label>38</label>
      <element-citation publication-type="journal" id="sref38">
        <person-group person-group-type="author">
          <name>
            <surname>Parca</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Pepe</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Pietrosanto</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Galvan</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Galli</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Palmeri</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Sciandrone</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Ferrè</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Ausiello</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Helmer-Citterich</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Modeling cancer drug response through drug-specific informative genes</article-title>
        <source>Sci. Rep.</source>
        <volume>9</volume>
        <year>2019</year>
        <fpage>15222</fpage>
        <pub-id pub-id-type="pmid">31645597</pub-id>
      </element-citation>
    </ref>
    <ref id="bib39">
      <label>39</label>
      <element-citation publication-type="journal" id="sref39">
        <person-group person-group-type="author">
          <name>
            <surname>Bolanos-Garcia</surname>
            <given-names>V.M.</given-names>
          </name>
          <name>
            <surname>Blundell</surname>
            <given-names>T.L.</given-names>
          </name>
        </person-group>
        <article-title>BUB1 and BUBR1: multifaceted kinases of the cell cycle</article-title>
        <source>Trends Biochem. Sci.</source>
        <volume>36</volume>
        <year>2011</year>
        <fpage>141</fpage>
        <lpage>150</lpage>
        <pub-id pub-id-type="pmid">20888775</pub-id>
      </element-citation>
    </ref>
    <ref id="bib40">
      <label>40</label>
      <element-citation publication-type="journal" id="sref40">
        <person-group person-group-type="author">
          <name>
            <surname>Izumi</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Matsumoto</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ikeuchi</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Saya</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Kajii</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Matsuura</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>BubR1 localizes to centrosomes and suppresses centrosome amplification via regulating Plk1 activity in interphase cells</article-title>
        <source>Oncogene</source>
        <volume>28</volume>
        <year>2009</year>
        <fpage>2806</fpage>
        <lpage>2820</lpage>
        <pub-id pub-id-type="pmid">19503101</pub-id>
      </element-citation>
    </ref>
    <ref id="bib41">
      <label>41</label>
      <element-citation publication-type="journal" id="sref41">
        <person-group person-group-type="author">
          <name>
            <surname>Keen</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Aurora-kinase inhibitors as anticancer agents</article-title>
        <source>Nat. Rev. Cancer</source>
        <volume>4</volume>
        <year>2004</year>
        <fpage>927</fpage>
        <lpage>936</lpage>
        <pub-id pub-id-type="pmid">15573114</pub-id>
      </element-citation>
    </ref>
    <ref id="bib42">
      <label>42</label>
      <element-citation publication-type="journal" id="sref42">
        <person-group person-group-type="author">
          <name>
            <surname>Prevo</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Pirovano</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Puliyadi</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Herbert</surname>
            <given-names>K.J.</given-names>
          </name>
          <name>
            <surname>Rodriguez-Berriguete</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>O’Docherty</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Greaves</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>McKenna</surname>
            <given-names>W.G.</given-names>
          </name>
          <name>
            <surname>Higgins</surname>
            <given-names>G.S.</given-names>
          </name>
        </person-group>
        <article-title>CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner</article-title>
        <source>Cell Cycle</source>
        <volume>17</volume>
        <year>2018</year>
        <fpage>1513</fpage>
        <lpage>1523</lpage>
        <pub-id pub-id-type="pmid">30045664</pub-id>
      </element-citation>
    </ref>
    <ref id="bib43">
      <label>43</label>
      <element-citation publication-type="journal" id="sref43">
        <person-group person-group-type="author">
          <name>
            <surname>Otto</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Sicinski</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>Cell cycle proteins as promising targets in cancer therapy</article-title>
        <source>Nat. Rev. Cancer</source>
        <volume>17</volume>
        <year>2017</year>
        <fpage>93</fpage>
        <lpage>115</lpage>
        <pub-id pub-id-type="pmid">28127048</pub-id>
      </element-citation>
    </ref>
    <ref id="bib44">
      <label>44</label>
      <element-citation publication-type="journal" id="sref44">
        <person-group person-group-type="author">
          <name>
            <surname>Beltran</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Oromendia</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Danila</surname>
            <given-names>D.C.</given-names>
          </name>
          <name>
            <surname>Montgomery</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Hoimes</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Szmulewitz</surname>
            <given-names>R.Z.</given-names>
          </name>
          <name>
            <surname>Vaishampayan</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Armstrong</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Stein</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Pinski</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers</article-title>
        <source>Clin. Cancer Res.</source>
        <volume>25</volume>
        <year>2019</year>
        <fpage>43</fpage>
        <lpage>51</lpage>
        <pub-id pub-id-type="pmid">30232224</pub-id>
      </element-citation>
    </ref>
    <ref id="bib45">
      <label>45</label>
      <element-citation publication-type="journal" id="sref45">
        <person-group person-group-type="author">
          <name>
            <surname>Diamond</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Eckhardt</surname>
            <given-names>S.G.</given-names>
          </name>
          <name>
            <surname>Pitts</surname>
            <given-names>T.M.</given-names>
          </name>
          <name>
            <surname>van Bokhoven</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Aisner</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Gustafson</surname>
            <given-names>D.L.</given-names>
          </name>
          <name>
            <surname>Capasso</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Sams</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Kabos</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Zolman</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer</article-title>
        <source>Breast Cancer Res.</source>
        <volume>20</volume>
        <year>2018</year>
        <fpage>82</fpage>
        <pub-id pub-id-type="pmid">30071865</pub-id>
      </element-citation>
    </ref>
    <ref id="bib46">
      <label>46</label>
      <element-citation publication-type="journal" id="sref46">
        <person-group person-group-type="author">
          <name>
            <surname>Sang</surname>
            <given-names>L.J.</given-names>
          </name>
          <name>
            <surname>Ju</surname>
            <given-names>H.Q.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>G.P.</given-names>
          </name>
          <name>
            <surname>Tian</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>G.L.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Y.X.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Z.X.</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>R.L.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>R.H.</given-names>
          </name>
          <name>
            <surname>Piao</surname>
            <given-names>H.L.</given-names>
          </name>
        </person-group>
        <article-title>LncRNA CamK-A Regulates Ca<sup>2+</sup>-Signaling-Mediated Tumor Microenvironment Remodeling</article-title>
        <source>Mol. Cell</source>
        <volume>72</volume>
        <year>2018</year>
        <fpage>601</fpage>
        <pub-id pub-id-type="pmid">30388414</pub-id>
      </element-citation>
    </ref>
    <ref id="bib47">
      <label>47</label>
      <element-citation publication-type="journal" id="sref47">
        <person-group person-group-type="author">
          <name>
            <surname>Owusu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bannauer</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Ferreira da Silva</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Mourikis</surname>
            <given-names>T.P.</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Majek</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Caldera</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wiedner</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Lardeau</surname>
            <given-names>C.-H.</given-names>
          </name>
          <name>
            <surname>Mueller</surname>
            <given-names>A.C.</given-names>
          </name>
        </person-group>
        <article-title>Mapping the Human Kinome in Response to DNA Damage</article-title>
        <source>Cell Rep.</source>
        <volume>26</volume>
        <year>2019</year>
        <fpage>555</fpage>
        <lpage>563.e6</lpage>
        <pub-id pub-id-type="pmid">30650350</pub-id>
      </element-citation>
    </ref>
    <ref id="bib48">
      <label>48</label>
      <element-citation publication-type="journal" id="sref48">
        <person-group person-group-type="author">
          <name>
            <surname>Rokhlin</surname>
            <given-names>O.W.</given-names>
          </name>
          <name>
            <surname>Guseva</surname>
            <given-names>N.V.</given-names>
          </name>
          <name>
            <surname>Taghiyev</surname>
            <given-names>A.F.</given-names>
          </name>
          <name>
            <surname>Glover</surname>
            <given-names>R.A.</given-names>
          </name>
          <name>
            <surname>Cohen</surname>
            <given-names>M.B.</given-names>
          </name>
        </person-group>
        <article-title>KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer</article-title>
        <source>Cancer Biol. Ther.</source>
        <volume>9</volume>
        <year>2010</year>
        <fpage>224</fpage>
        <lpage>235</lpage>
        <pub-id pub-id-type="pmid">20023417</pub-id>
      </element-citation>
    </ref>
    <ref id="bib49">
      <label>49</label>
      <element-citation publication-type="journal" id="sref49">
        <person-group person-group-type="author">
          <name>
            <surname>Rodriguez-Mora</surname>
            <given-names>O.G.</given-names>
          </name>
          <name>
            <surname>LaHair</surname>
            <given-names>M.M.</given-names>
          </name>
          <name>
            <surname>McCubrey</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Franklin</surname>
            <given-names>R.A.</given-names>
          </name>
        </person-group>
        <article-title>Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells</article-title>
        <source>Cancer Res.</source>
        <volume>65</volume>
        <year>2005</year>
        <fpage>5408</fpage>
        <lpage>5416</lpage>
        <pub-id pub-id-type="pmid">15958590</pub-id>
      </element-citation>
    </ref>
    <ref id="bib50">
      <label>50</label>
      <element-citation publication-type="journal" id="sref50">
        <person-group person-group-type="author">
          <name>
            <surname>Rivalland</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Mitchell</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>Combined BRAF and MEK inhibition in BRAF-mutant NSCLC</article-title>
        <source>Lancet Oncol.</source>
        <volume>17</volume>
        <year>2016</year>
        <fpage>860</fpage>
        <lpage>862</lpage>
        <pub-id pub-id-type="pmid">27283865</pub-id>
      </element-citation>
    </ref>
    <ref id="bib51">
      <label>51</label>
      <element-citation publication-type="journal" id="sref51">
        <person-group person-group-type="author">
          <name>
            <surname>Torkamani</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Verkhivker</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Schork</surname>
            <given-names>N.J.</given-names>
          </name>
        </person-group>
        <article-title>Cancer driver mutations in protein kinase genes</article-title>
        <source>Cancer Lett.</source>
        <volume>281</volume>
        <year>2009</year>
        <fpage>117</fpage>
        <lpage>127</lpage>
        <pub-id pub-id-type="pmid">19081671</pub-id>
      </element-citation>
    </ref>
    <ref id="bib52">
      <label>52</label>
      <element-citation publication-type="journal" id="sref52">
        <person-group person-group-type="author">
          <name>
            <surname>Mayakonda</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>D.C.</given-names>
          </name>
          <name>
            <surname>Assenov</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Plass</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Koeffler</surname>
            <given-names>H.P.</given-names>
          </name>
        </person-group>
        <article-title>Maftools: efficient and comprehensive analysis of somatic variants in cancer</article-title>
        <source>Genome Res.</source>
        <volume>28</volume>
        <year>2018</year>
        <fpage>1747</fpage>
        <lpage>1756</lpage>
        <pub-id pub-id-type="pmid">30341162</pub-id>
      </element-citation>
    </ref>
    <ref id="bib53">
      <label>53</label>
      <element-citation publication-type="journal" id="sref53">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Chong</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Meric-Bernstam</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Mills</surname>
            <given-names>G.B.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types</article-title>
        <source>BMC Genomics</source>
        <volume>17</volume>
        <year>2016</year>
        <fpage>394</fpage>
        <pub-id pub-id-type="pmid">27356755</pub-id>
      </element-citation>
    </ref>
    <ref id="bib54">
      <label>54</label>
      <element-citation publication-type="journal" id="sref54">
        <person-group person-group-type="author">
          <name>
            <surname>Stirrups</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer</article-title>
        <source>Lancet Oncol.</source>
        <volume>20</volume>
        <year>2019</year>
        <fpage>e347</fpage>
        <pub-id pub-id-type="pmid">31130321</pub-id>
      </element-citation>
    </ref>
    <ref id="bib55">
      <label>55</label>
      <element-citation publication-type="journal" id="sref55">
        <person-group person-group-type="author">
          <name>
            <surname>Xing</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>N.U.</given-names>
          </name>
          <name>
            <surname>Maurer</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Mahvash</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Sahin</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Akcakanat</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Abramson</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Litton</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation</article-title>
        <source>Breast Cancer Res.</source>
        <volume>21</volume>
        <year>2019</year>
        <fpage>78</fpage>
        <pub-id pub-id-type="pmid">31277699</pub-id>
      </element-citation>
    </ref>
    <ref id="bib56">
      <label>56</label>
      <element-citation publication-type="journal" id="sref56">
        <person-group person-group-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>J.C.</given-names>
          </name>
          <name>
            <surname>Sheltzer</surname>
            <given-names>J.M.</given-names>
          </name>
        </person-group>
        <article-title>Systematic identification of mutations and copy number alterations associated with cancer patient prognosis</article-title>
        <source>eLife</source>
        <volume>7</volume>
        <year>2018</year>
        <fpage>e39217</fpage>
        <pub-id pub-id-type="pmid">30526857</pub-id>
      </element-citation>
    </ref>
    <ref id="bib57">
      <label>57</label>
      <element-citation publication-type="journal" id="sref57">
        <person-group person-group-type="author">
          <name>
            <surname>Vogelstein</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Papadopoulos</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Velculescu</surname>
            <given-names>V.E.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Diaz</surname>
            <given-names>L.A.</given-names>
            <suffix>Jr.</suffix>
          </name>
          <name>
            <surname>Kinzler</surname>
            <given-names>K.W.</given-names>
          </name>
        </person-group>
        <article-title>Cancer genome landscapes</article-title>
        <source>Science</source>
        <volume>339</volume>
        <year>2013</year>
        <fpage>1546</fpage>
        <lpage>1558</lpage>
        <pub-id pub-id-type="pmid">23539594</pub-id>
      </element-citation>
    </ref>
    <ref id="bib58">
      <label>58</label>
      <element-citation publication-type="journal" id="sref58">
        <person-group person-group-type="author">
          <name>
            <surname>Mermel</surname>
            <given-names>C.H.</given-names>
          </name>
          <name>
            <surname>Schumacher</surname>
            <given-names>S.E.</given-names>
          </name>
          <name>
            <surname>Hill</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Meyerson</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Beroukhim</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Getz</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers</article-title>
        <source>Genome Biol.</source>
        <volume>12</volume>
        <year>2011</year>
        <fpage>R41</fpage>
        <pub-id pub-id-type="pmid">21527027</pub-id>
      </element-citation>
    </ref>
    <ref id="bib59">
      <label>59</label>
      <element-citation publication-type="journal" id="sref59">
        <person-group person-group-type="author">
          <name>
            <surname>Goossens</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Nakagawa</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Hoshida</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>Cancer biomarker discovery and validation</article-title>
        <source>Transl. Cancer Res.</source>
        <volume>4</volume>
        <year>2015</year>
        <fpage>256</fpage>
        <lpage>269</lpage>
        <pub-id pub-id-type="pmid">26213686</pub-id>
      </element-citation>
    </ref>
    <ref id="bib60">
      <label>60</label>
      <element-citation publication-type="journal" id="sref60">
        <person-group person-group-type="author">
          <name>
            <surname>Hong</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Gong</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>TRIB3 Promotes the Proliferation and Invasion of Renal Cell Carcinoma Cells via Activating MAPK Signaling Pathway</article-title>
        <source>Int. J. Biol. Sci.</source>
        <volume>15</volume>
        <year>2019</year>
        <fpage>587</fpage>
        <lpage>597</lpage>
        <pub-id pub-id-type="pmid">30745845</pub-id>
      </element-citation>
    </ref>
    <ref id="bib61">
      <label>61</label>
      <element-citation publication-type="journal" id="sref61">
        <person-group person-group-type="author">
          <name>
            <surname>Hua</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>J.J.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Z.W.</given-names>
          </name>
        </person-group>
        <article-title>The TRIB3-SQSTM1 interaction mediates metabolic stress-promoted tumorigenesis and progression via suppressing autophagic and proteasomal degradation</article-title>
        <source>Autophagy</source>
        <volume>11</volume>
        <year>2015</year>
        <fpage>1929</fpage>
        <lpage>1931</lpage>
        <pub-id pub-id-type="pmid">26301314</pub-id>
      </element-citation>
    </ref>
    <ref id="bib62">
      <label>62</label>
      <element-citation publication-type="journal" id="sref62">
        <person-group person-group-type="author">
          <name>
            <surname>Wennemers</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bussink</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Scheijen</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Nagtegaal</surname>
            <given-names>I.D.</given-names>
          </name>
          <name>
            <surname>van Laarhoven</surname>
            <given-names>H.W.</given-names>
          </name>
          <name>
            <surname>Raleigh</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Varia</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Heuvel</surname>
            <given-names>J.J.</given-names>
          </name>
          <name>
            <surname>Rouschop</surname>
            <given-names>K.M.</given-names>
          </name>
          <name>
            <surname>Sweep</surname>
            <given-names>F.C.</given-names>
          </name>
          <name>
            <surname>Span</surname>
            <given-names>P.N.</given-names>
          </name>
        </person-group>
        <article-title>Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response</article-title>
        <source>Breast Cancer Res.</source>
        <volume>13</volume>
        <year>2011</year>
        <fpage>R82</fpage>
        <pub-id pub-id-type="pmid">21864376</pub-id>
      </element-citation>
    </ref>
    <ref id="bib63">
      <label>63</label>
      <element-citation publication-type="journal" id="sref63">
        <person-group person-group-type="author">
          <name>
            <surname>Lin</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Xiong</surname>
            <given-names>D.D.</given-names>
          </name>
          <name>
            <surname>Dang</surname>
            <given-names>Y.W.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>D.Y.</given-names>
          </name>
          <name>
            <surname>Qin</surname>
            <given-names>X.G.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation</article-title>
        <source>Oncotarget</source>
        <volume>8</volume>
        <year>2017</year>
        <fpage>92497</fpage>
        <lpage>92521</lpage>
        <pub-id pub-id-type="pmid">29190933</pub-id>
      </element-citation>
    </ref>
    <ref id="bib64">
      <label>64</label>
      <element-citation publication-type="journal" id="sref64">
        <person-group person-group-type="author">
          <name>
            <surname>Mobley</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Bondaruk</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Majewski</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Caraway</surname>
            <given-names>N.P.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Shoshan</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Velazquez-Torres</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Nitti</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior</article-title>
        <source>Sci. Rep.</source>
        <volume>7</volume>
        <year>2017</year>
        <fpage>40714</fpage>
        <pub-id pub-id-type="pmid">28102366</pub-id>
      </element-citation>
    </ref>
    <ref id="bib65">
      <label>65</label>
      <element-citation publication-type="journal" id="sref65">
        <person-group person-group-type="author">
          <name>
            <surname>Hughes</surname>
            <given-names>J.P.</given-names>
          </name>
          <name>
            <surname>Rees</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Kalindjian</surname>
            <given-names>S.B.</given-names>
          </name>
          <name>
            <surname>Philpott</surname>
            <given-names>K.L.</given-names>
          </name>
        </person-group>
        <article-title>Principles of early drug discovery</article-title>
        <source>Br. J. Pharmacol.</source>
        <volume>162</volume>
        <year>2011</year>
        <fpage>1239</fpage>
        <lpage>1249</lpage>
        <pub-id pub-id-type="pmid">21091654</pub-id>
      </element-citation>
    </ref>
    <ref id="bib66">
      <label>66</label>
      <element-citation publication-type="journal" id="sref66">
        <person-group person-group-type="author">
          <name>
            <surname>Plenge</surname>
            <given-names>R.M.</given-names>
          </name>
          <name>
            <surname>Scolnick</surname>
            <given-names>E.M.</given-names>
          </name>
          <name>
            <surname>Altshuler</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>Validating therapeutic targets through human genetics</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <volume>12</volume>
        <year>2013</year>
        <fpage>581</fpage>
        <lpage>594</lpage>
        <pub-id pub-id-type="pmid">23868113</pub-id>
      </element-citation>
    </ref>
    <ref id="bib67">
      <label>67</label>
      <element-citation publication-type="journal" id="sref67">
        <person-group person-group-type="author">
          <name>
            <surname>Gashaw</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Ellinghaus</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Sommer</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Asadullah</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>What makes a good drug target?</article-title>
        <source>Drug Discov. Today</source>
        <volume>17</volume>
        <year>2012</year>
        <fpage>S24</fpage>
        <lpage>S30</lpage>
        <pub-id pub-id-type="pmid">22155646</pub-id>
      </element-citation>
    </ref>
    <ref id="bib68">
      <label>68</label>
      <element-citation publication-type="journal" id="sref68">
        <person-group person-group-type="author">
          <name>
            <surname>Carithers</surname>
            <given-names>L.J.</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>H.M.</given-names>
          </name>
        </person-group>
        <article-title>The Genotype-Tissue Expression (GTEx) Project</article-title>
        <source>Biopreserv. Biobank.</source>
        <volume>13</volume>
        <year>2015</year>
        <fpage>307</fpage>
        <lpage>308</lpage>
        <pub-id pub-id-type="pmid">26484569</pub-id>
      </element-citation>
    </ref>
    <ref id="bib69">
      <label>69</label>
      <element-citation publication-type="journal" id="sref69">
        <person-group person-group-type="author">
          <name>
            <surname>Uhlén</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Fagerberg</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Hallström</surname>
            <given-names>B.M.</given-names>
          </name>
          <name>
            <surname>Lindskog</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Oksvold</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Mardinoglu</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Sivertsson</surname>
            <given-names>Å.</given-names>
          </name>
          <name>
            <surname>Kampf</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Sjöstedt</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Asplund</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Proteomics. Tissue-based map of the human proteome</article-title>
        <source>Science</source>
        <volume>347</volume>
        <year>2015</year>
        <fpage>1260419</fpage>
        <pub-id pub-id-type="pmid">25613900</pub-id>
      </element-citation>
    </ref>
    <ref id="bib70">
      <label>70</label>
      <element-citation publication-type="journal" id="sref70">
        <person-group person-group-type="author">
          <name>
            <surname>Du</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Lovly</surname>
            <given-names>C.M.</given-names>
          </name>
        </person-group>
        <article-title>Mechanisms of receptor tyrosine kinase activation in cancer</article-title>
        <source>Mol. Cancer</source>
        <volume>17</volume>
        <year>2018</year>
        <fpage>58</fpage>
        <pub-id pub-id-type="pmid">29455648</pub-id>
      </element-citation>
    </ref>
    <ref id="bib71">
      <label>71</label>
      <element-citation publication-type="journal" id="sref71">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Beyer</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Aebersold</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>On the Dependency of Cellular Protein Levels on mRNA Abundance</article-title>
        <source>Cell</source>
        <volume>165</volume>
        <year>2016</year>
        <fpage>535</fpage>
        <lpage>550</lpage>
        <pub-id pub-id-type="pmid">27104977</pub-id>
      </element-citation>
    </ref>
    <ref id="bib72">
      <label>72</label>
      <element-citation publication-type="journal" id="sref72">
        <person-group person-group-type="author">
          <name>
            <surname>Schmidt</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Rohe</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Platzer</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Najjar</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Erdmann</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Sippl</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases</article-title>
        <source>Molecules</source>
        <volume>22</volume>
        <year>2017</year>
        <fpage>E2045</fpage>
        <pub-id pub-id-type="pmid">29168755</pub-id>
      </element-citation>
    </ref>
    <ref id="bib73">
      <label>73</label>
      <element-citation publication-type="journal" id="sref73">
        <person-group person-group-type="author">
          <name>
            <surname>Ma’ayan</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>PKMYT1 is a computationally predicted target for kidney cancer</article-title>
        <source>bioRxiv</source>
        <year>2019</year>
        <pub-id pub-id-type="doi">10.1101/677245</pub-id>
      </element-citation>
    </ref>
    <ref id="bib74">
      <label>74</label>
      <element-citation publication-type="journal" id="sref74">
        <person-group person-group-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Ursu</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Gaulton</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Bento</surname>
            <given-names>A.P.</given-names>
          </name>
          <name>
            <surname>Donadi</surname>
            <given-names>R.S.</given-names>
          </name>
          <name>
            <surname>Bologa</surname>
            <given-names>C.G.</given-names>
          </name>
          <name>
            <surname>Karlsson</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Al-Lazikani</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Hersey</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Oprea</surname>
            <given-names>T.I.</given-names>
          </name>
          <name>
            <surname>Overington</surname>
            <given-names>J.P.</given-names>
          </name>
        </person-group>
        <article-title>A comprehensive map of molecular drug targets</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <volume>16</volume>
        <year>2017</year>
        <fpage>19</fpage>
        <lpage>34</lpage>
        <pub-id pub-id-type="pmid">27910877</pub-id>
      </element-citation>
    </ref>
    <ref id="bib75">
      <label>75</label>
      <element-citation publication-type="journal" id="sref75">
        <person-group person-group-type="author">
          <name>
            <surname>Markham</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Erdafitinib: First Global Approval</article-title>
        <source>Drugs</source>
        <volume>79</volume>
        <year>2019</year>
        <fpage>1017</fpage>
        <lpage>1021</lpage>
        <pub-id pub-id-type="pmid">31161538</pub-id>
      </element-citation>
    </ref>
    <ref id="bib76">
      <label>76</label>
      <element-citation publication-type="journal" id="sref76">
        <person-group person-group-type="author">
          <name>
            <surname>Collado-Torres</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Nellore</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Kammers</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Ellis</surname>
            <given-names>S.E.</given-names>
          </name>
          <name>
            <surname>Taub</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Hansen</surname>
            <given-names>K.D.</given-names>
          </name>
          <name>
            <surname>Jaffe</surname>
            <given-names>A.E.</given-names>
          </name>
          <name>
            <surname>Langmead</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Leek</surname>
            <given-names>J.T.</given-names>
          </name>
        </person-group>
        <article-title>Reproducible RNA-seq analysis using recount2</article-title>
        <source>Nat. Biotechnol.</source>
        <volume>35</volume>
        <year>2017</year>
        <fpage>319</fpage>
        <lpage>321</lpage>
        <pub-id pub-id-type="pmid">28398307</pub-id>
      </element-citation>
    </ref>
    <ref id="bib77">
      <label>77</label>
      <element-citation publication-type="journal" id="sref77">
        <person-group person-group-type="author">
          <name>
            <surname>Ritchie</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Phipson</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Law</surname>
            <given-names>C.W.</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Smyth</surname>
            <given-names>G.K.</given-names>
          </name>
        </person-group>
        <article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>43</volume>
        <year>2015</year>
        <fpage>e47</fpage>
        <pub-id pub-id-type="pmid">25605792</pub-id>
      </element-citation>
    </ref>
    <ref id="bib78">
      <label>78</label>
      <element-citation publication-type="journal" id="sref78">
        <person-group person-group-type="author">
          <name>
            <surname>Amin</surname>
            <given-names>M.B.</given-names>
          </name>
          <name>
            <surname>Greene</surname>
            <given-names>F.L.</given-names>
          </name>
          <name>
            <surname>Edge</surname>
            <given-names>S.B.</given-names>
          </name>
          <name>
            <surname>Compton</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>Gershenwald</surname>
            <given-names>J.E.</given-names>
          </name>
          <name>
            <surname>Brookland</surname>
            <given-names>R.K.</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Gress</surname>
            <given-names>D.M.</given-names>
          </name>
          <name>
            <surname>Byrd</surname>
            <given-names>D.R.</given-names>
          </name>
          <name>
            <surname>Winchester</surname>
            <given-names>D.P.</given-names>
          </name>
        </person-group>
        <article-title>The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging</article-title>
        <source>CA Cancer J. Clin.</source>
        <volume>67</volume>
        <year>2017</year>
        <fpage>93</fpage>
        <lpage>99</lpage>
        <pub-id pub-id-type="pmid">28094848</pub-id>
      </element-citation>
    </ref>
    <ref id="bib79">
      <label>79</label>
      <element-citation publication-type="journal" id="sref79">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lichtenberg</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Hoadley</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Poisson</surname>
            <given-names>L.M.</given-names>
          </name>
          <name>
            <surname>Lazar</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Cherniack</surname>
            <given-names>A.D.</given-names>
          </name>
          <name>
            <surname>Kovatich</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Benz</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>Levine</surname>
            <given-names>D.A.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>A.V.</given-names>
          </name>
        </person-group>
        <article-title>An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics</article-title>
        <source>Cell</source>
        <volume>173</volume>
        <year>2018</year>
        <fpage>400</fpage>
        <lpage>416.e11</lpage>
        <pub-id pub-id-type="pmid">29625055</pub-id>
      </element-citation>
    </ref>
    <ref id="bib80">
      <label>80</label>
      <element-citation publication-type="journal" id="sref80">
        <person-group person-group-type="author">
          <name>
            <surname>Grossman</surname>
            <given-names>R.L.</given-names>
          </name>
          <name>
            <surname>Heath</surname>
            <given-names>A.P.</given-names>
          </name>
          <name>
            <surname>Ferretti</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Varmus</surname>
            <given-names>H.E.</given-names>
          </name>
          <name>
            <surname>Lowy</surname>
            <given-names>D.R.</given-names>
          </name>
          <name>
            <surname>Kibbe</surname>
            <given-names>W.A.</given-names>
          </name>
          <name>
            <surname>Staudt</surname>
            <given-names>L.M.</given-names>
          </name>
        </person-group>
        <article-title>Toward a Shared Vision for Cancer Genomic Data</article-title>
        <source>N. Engl. J. Med.</source>
        <volume>375</volume>
        <year>2016</year>
        <fpage>1109</fpage>
        <lpage>1112</lpage>
        <pub-id pub-id-type="pmid">27653561</pub-id>
      </element-citation>
    </ref>
    <ref id="bib81">
      <label>81</label>
      <element-citation publication-type="journal" id="sref81">
        <person-group person-group-type="author">
          <name>
            <surname>Gentleman</surname>
            <given-names>R.C.</given-names>
          </name>
          <name>
            <surname>Carey</surname>
            <given-names>V.J.</given-names>
          </name>
          <name>
            <surname>Bates</surname>
            <given-names>D.M.</given-names>
          </name>
          <name>
            <surname>Bolstad</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Dettling</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Dudoit</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ellis</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Gautier</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Ge</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Gentry</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Bioconductor: open software development for computational biology and bioinformatics</article-title>
        <source>Genome Biol.</source>
        <volume>5</volume>
        <year>2004</year>
        <fpage>R80</fpage>
        <pub-id pub-id-type="pmid">15461798</pub-id>
      </element-citation>
    </ref>
    <ref id="bib82">
      <label>82</label>
      <element-citation publication-type="journal" id="sref82">
        <person-group person-group-type="author">
          <name>
            <surname>Colaprico</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Silva</surname>
            <given-names>T.C.</given-names>
          </name>
          <name>
            <surname>Olsen</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Garofano</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Cava</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Garolini</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Sabedot</surname>
            <given-names>T.S.</given-names>
          </name>
          <name>
            <surname>Malta</surname>
            <given-names>T.M.</given-names>
          </name>
          <name>
            <surname>Pagnotta</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Castiglioni</surname>
            <given-names>I.</given-names>
          </name>
        </person-group>
        <article-title>TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>44</volume>
        <year>2016</year>
        <fpage>e71</fpage>
        <pub-id pub-id-type="pmid">26704973</pub-id>
      </element-citation>
    </ref>
    <ref id="bib83">
      <label>83</label>
      <element-citation publication-type="book" id="sref83">
        <person-group person-group-type="author">
          <name>
            <surname>Therneau</surname>
            <given-names>T.M.</given-names>
          </name>
          <name>
            <surname>Grambsch</surname>
            <given-names>P.M.</given-names>
          </name>
        </person-group>
        <chapter-title>Modeling survival data: extending the Cox model</chapter-title>
        <year>2000</year>
        <publisher-name>Springer</publisher-name>
      </element-citation>
    </ref>
    <ref id="bib84">
      <label>84</label>
      <element-citation publication-type="journal" id="sref84">
        <person-group person-group-type="author">
          <name>
            <surname>Porta-Pardo</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Godzik</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>e-Driver: a novel method to identify protein regions driving cancer</article-title>
        <source>Bioinformatics</source>
        <volume>30</volume>
        <year>2014</year>
        <fpage>3109</fpage>
        <lpage>3114</lpage>
        <pub-id pub-id-type="pmid">25064568</pub-id>
      </element-citation>
    </ref>
    <ref id="bib85">
      <label>85</label>
      <element-citation publication-type="journal" id="sref85">
        <person-group person-group-type="author">
          <name>
            <surname>Cerami</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Dogrusoz</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Gross</surname>
            <given-names>B.E.</given-names>
          </name>
          <name>
            <surname>Sumer</surname>
            <given-names>S.O.</given-names>
          </name>
          <name>
            <surname>Aksoy</surname>
            <given-names>B.A.</given-names>
          </name>
          <name>
            <surname>Jacobsen</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Byrne</surname>
            <given-names>C.J.</given-names>
          </name>
          <name>
            <surname>Heuer</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Larsson</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title>
        <source>Cancer Discov.</source>
        <volume>2</volume>
        <year>2012</year>
        <fpage>401</fpage>
        <lpage>404</lpage>
        <pub-id pub-id-type="pmid">22588877</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="appsec2" sec-type="supplementary-material">
    <title>Supplemental Information</title>
    <p id="p0315">
      <supplementary-material content-type="local-data" id="mmc1">
        <caption>
          <title>Document S1. Figure S1</title>
        </caption>
        <media xlink:href="mmc1.pdf"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="mmc2">
        <caption>
          <title>Table S1. TCGA Data Overview, Related to Figure 1 and STAR Methods</title>
        </caption>
        <media xlink:href="mmc2.xlsx"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="mmc3">
        <caption>
          <title>Table S2. MOA Target Analysis, Related to STAR Methods</title>
        </caption>
        <media xlink:href="mmc3.xlsx"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="mmc4">
        <caption>
          <title>Table S3. Dependency Map Analysis, Related to Figure 5 and STAR Methods</title>
        </caption>
        <media xlink:href="mmc4.xlsx"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="mmc5">
        <caption>
          <title>Table S4. Differential Gene Expression Analysis, Related to Figure 6A and STAR Methods</title>
        </caption>
        <media xlink:href="mmc5.xlsx"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="mmc6">
        <caption>
          <title>Table S5. Hot-Spot Mutation and CAN Analysis, Related to Figure 6D and STAR Methods</title>
        </caption>
        <media xlink:href="mmc6.xlsx"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="mmc7">
        <caption>
          <title>Table S6. Kaplan-Meier Survival Analysis, Related to Figure 6B and STAR Methods</title>
        </caption>
        <media xlink:href="mmc7.xlsx"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="mmc8">
        <caption>
          <title>Table S7. CKI Score per Parameter, Related to Figure 3 and STAR Methods</title>
        </caption>
        <media xlink:href="mmc8.xlsx"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="mmc9">
        <caption>
          <title>Document S2. Article plus Supplemental Information</title>
        </caption>
        <media xlink:href="mmc9.pdf"/>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ack0010">
    <title>Acknowledgments</title>
    <p id="p0295">This work was supported by <funding-source id="gs1">NIH</funding-source> grants U54HL127624 (BD2K LINCS Data Coordination and Integration Center, DCIC), U24TR002278 (Illuminating the Druggable Genome Resource Dissemination and Outreach Center, IDG-RDOC), U01LM012630 (BD2K, Enhancing the efficiency and effectiveness of digital curation for biomedical ‘big data’), and P30CA240139 (NCI Sylvester Cancer Center Support Grant), and the <funding-source id="gs2">State of Florida Biomedical Research Program</funding-source>, Bankhead Coley grant 9BC13.</p>
    <sec id="sec5">
      <title>Author Contributions</title>
      <p id="p0300">D.E., V.S., and S.C.S. conceived the project, and R.K. carried out statistical analyses. D.E. and S.C.S. analyzed and interpreted data, and R.K. developed the web app. D.E. wrote the manuscript, and D.E., V.S., and R.K. made figures.</p>
    </sec>
    <sec sec-type="COI-statement" id="sec6">
      <title>Declaration of Interests</title>
      <p id="p0305">The authors declare no competing interests.</p>
    </sec>
  </ack>
  <fn-group>
    <fn id="appsec1" fn-type="supplementary-material">
      <p id="p0310">Supplemental Information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.xcrm.2020.100128" id="intref0125">https://doi.org/10.1016/j.xcrm.2020.100128</ext-link>.</p>
    </fn>
  </fn-group>
</back>
